Document:

exv4w2

Exhibit 4.2

	 	 	 	 	 

REGISTRATION RIGHTS AGREEMENT

     This REGISTRATION RIGHTS AGREEMENT dated September 19, 2011 (this “Agreement”) is entered into
by and among Calumet Specialty Products Partners, L.P., a Delaware limited partnership (the
“Partnership”), Calumet Finance Corp., a Delaware corporation (“Calumet Finance,” and together with
the Partnership, the “Issuers”), the guarantors listed on the signature pages hereto (the
“Guarantors”), and Merrill Lynch, Pierce, Fenner & Smith, Incorporated (“Merrill Lynch”), Barclays
Capital Inc., J.P. Morgan Securities LLC, Deutsche Bank Securities Inc. and Wells Fargo Securities,
LLC (collectively, the “Initial Purchasers”). The Issuers and the Guarantors are hereinafter
referred to collectively as the “Calumet Parties.”

     The Calumet Parties and the Initial Purchasers are parties to the Purchase Agreement dated
September 8, 2011 (the “Purchase Agreement”), which provides for the sale by the Issuers to the
Initial Purchasers of $200,000,000 aggregate principal amount of the Issuers’ 9 3/8% Senior Notes
due 2019 (the “Securities”) which will be guaranteed on an unsecured senior basis by each of the
Guarantors. As an inducement to the Initial Purchasers to enter into the Purchase Agreement, the
Calumet Parties have agreed to provide to the Initial Purchasers and their direct and indirect
transferees the registration rights set forth in this Agreement. The execution and delivery of
this Agreement is a condition to the closing under the Purchase Agreement.

     In consideration of the foregoing, the parties hereto agree as follows:

     1. Definitions. As used in this Agreement, the following terms shall have the
following meanings:

     “Additional Guarantor” shall mean any subsidiary of the Partnership that executes a Subsidiary
Guarantee under the Indenture after the date of this Agreement.

     “Business Day” shall mean any day that is not a Saturday, Sunday or other day on which
commercial banks in New York City are authorized or required by law to remain closed.

     “Calumet Finance” shall have the meaning set forth in the preamble and shall also include
Calumet Finance’s successors.

     “Calumet Parties” shall have the meaning set forth in the preamble.

     “DTC” shall mean the Depository Trust Company.

     “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time.

     “Exchange Dates” shall have the meaning set forth in Section 2(a)(ii) hereof.

     “Exchange Offer” shall mean the exchange offer by the Calumet Parties of Exchange Securities
for Registrable Securities pursuant to Section 2(a) hereof.

 

 

     “Exchange Offer Registration” shall mean a registration under the Securities Act effected
pursuant to Section 2(a) hereof.

     “Exchange Offer Registration Statement” shall mean an exchange offer registration statement on
Form S-4 (or, if applicable, on another appropriate form) and all amendments and supplements to
such registration statement, in each case including the Prospectus contained therein, all exhibits
thereto and any document incorporated by reference therein.

     “Exchange Securities” shall mean senior notes issued by the Issuers and guaranteed by the
Guarantors under the Indenture containing terms identical to the Securities (except that the
Exchange Securities will not be subject to restrictions on transfer or to any increase in annual
interest rate for failure to comply with this Agreement) and to be offered to Holders of Securities
in exchange for Securities pursuant to the Exchange Offer.

     “Guarantors” shall have the meaning set forth in the preamble and shall also include any
Guarantor’s successors and any Additional Guarantors.

     “Holders” shall mean the Initial Purchasers, for so long as they own any Registrable
Securities, and each of their successors, assigns and direct and indirect transferees who become
owners of Registrable Securities under the Indenture; provided that for purposes of Sections 4 and
5 of this Agreement, the term “Holders” shall include Participating Broker-Dealers.

     “Indemnified Person” shall have the meaning set forth in Section 5(c) hereof.

     “Indemnifying Person” shall have the meaning set forth in Section 5(c) hereof.

     “Indenture” shall mean the Indenture relating to the Securities dated as of September 19, 2011
among the Calumet Parties and Wilmington Trust, National Association, as trustee, and as the same
may be amended from time to time in accordance with the terms thereof.

     “Initial Purchasers” shall have the meaning set forth in the preamble.

     “Inspector” shall have the meaning set forth in Section 3(a)(xiii) hereof.

     “Issuer Information” shall have the meaning set forth in Section 5(a) hereof.

     “Issuers” shall have the meaning set forth in the preamble.

     “Merrill Lynch” shall have the meaning set forth in the preamble.

     “Majority Holders” shall mean the Holders of a majority of the aggregate principal amount of
the outstanding Registrable Securities; provided that whenever the consent or approval of Holders
of a specified percentage of Registrable Securities is required hereunder, any Registrable
Securities owned directly or indirectly by the Issuers or any of their affiliates shall not be
counted in determining whether such consent or approval was given by the Holders of
such required percentage or amount; and provided, further, that if the Issuers shall issue any
additional Securities under the Indenture prior to consummation of the Exchange Offer or, if
applicable, the effectiveness of any Shelf Registration Statement, such additional Securities and

2

 

the Registrable Securities to which this Agreement relates shall be treated together as one class
for purposes of determining whether the consent or approval of Holders of a specified percentage of
Registrable Securities has been obtained.

     “Participating Broker-Dealers” shall have the meaning set forth in Section 4(a) hereof.

     “Partnership” shall have the meaning set forth in the preamble and shall also include the
Partnership’s successors.

     “Person” shall mean an individual, partnership, limited liability company, corporation, trust
or unincorporated organization, or a government or agency or political subdivision thereof.

     “Prospectus” shall mean the prospectus included in, or deemed a part of, a Registration
Statement, including any preliminary prospectus, and any such prospectus as amended or supplemented
by any prospectus supplement, including a prospectus supplement with respect to the terms of the
offering of any portion of the Registrable Securities covered by a Shelf Registration Statement,
and by all other amendments and supplements to such prospectus, and in each case including any
document incorporated by reference therein.

     “Purchase Agreement” shall have the meaning set forth in the recital.

     “Registrable Securities” shall mean the Securities; provided that the Securities shall cease
to be Registrable Securities on the earliest of (i) when a Registration Statement with respect to
such Securities has been declared effective by the SEC and such Securities have been exchanged or
disposed of pursuant to such Registration Statement, (ii) if an Exchange Offer is completed, on or
after the Exchange Date with respect to the Holders that are eligible to participate in the
Exchange Offer but fail to tender such Securities in the Exchange Offer, (iii) the date that is two
years from the original issue date of the Securities or (iv) when such Securities cease to be
outstanding.

     “Registration Expenses” shall mean any and all expenses incident to performance of or
compliance by the Calumet Parties with this Agreement, including without limitation: (i) all SEC,
stock exchange or Financial Industry Regulatory Authority, Inc. registration and filing fees, (ii)
all fees and expenses incurred in connection with compliance with state securities or blue sky laws
(including reasonable fees and disbursements of counsel for any Underwriters or Holders in
connection with blue sky qualification of any Exchange Securities or Registrable Securities), (iii)
all expenses of any Persons in preparing or assisting in preparing, word processing, printing and
distributing any Registration Statement, any Prospectus and any amendments or supplements thereto,
any underwriting agreements, securities sales agreements or other similar agreements and any other
documents relating to the performance of and compliance with this Agreement, (iv) all rating agency
fees, (v) all fees and disbursements relating to the qualification of the Indenture under
applicable securities laws, including the Trust Indenture Act, (vi) the fees and disbursements of
the Trustee and its counsel, (vii) the fees and disbursements of counsel for the Calumet Parties
and, in the case of a Shelf Registration Statement, the fees and disbursements of
one counsel for the Holders (which counsel shall be selected by the Majority Holders and which
counsel may also be counsel for the Initial Purchasers) and (viii) the fees and disbursements of
the independent public accountants of the Calumet Parties, including the expenses of any special

3

 

audits or “comfort” letters required by or incident to the performance of and compliance with this
Agreement, but excluding fees and expenses of counsel to the Underwriters (other than fees and
expenses set forth in clause (ii) above) or the Holders and underwriting discounts and commissions,
brokerage commissions and transfer taxes, if any, relating to the sale or disposition of
Registrable Securities by a Holder.

     “Registration Statement” shall mean any registration statement filed under the Securities Act
of the Calumet Parties that covers any of the Exchange Securities or Registrable Securities
pursuant to the provisions of this Agreement and all amendments and supplements to any such
registration statement, including post-effective amendments, in each case including the Prospectus
contained therein, all exhibits thereto and any document incorporated by reference therein.

     “SEC” shall mean the United States Securities and Exchange Commission.

     “Securities” shall have the meaning set forth in the recital.

     “Securities Act” shall mean the Securities Act of 1933, as amended from time to time.

     “Shelf Effectiveness Period” shall have the meaning set forth in Section 2(b) hereof.

     “Shelf Registration” shall mean a registration effected pursuant to Section 2(b) hereof.

     “Shelf Registration Statement” shall mean a “shelf” registration statement of the Calumet
Parties that covers all or a portion of the Registrable Securities (but no other securities unless
approved by the Holders of a majority of the Registrable Securities to be covered by such Shelf
Registration Statement) on an appropriate form under Rule 415 under the Securities Act, or any
similar rule that may be adopted by the SEC, and all amendments and supplements to such
registration statement, including post-effective amendments, in each case including the Prospectus
contained therein or deemed a part thereof, all exhibits thereto and any document incorporated by
reference therein.

     “Shelf Request” shall have the meaning set forth in Section 2(b) hereof.

     “Subsidiary Guarantees” shall mean the guarantees of the Securities and Exchange Securities by
the Guarantors under the Indenture.

     “Staff” shall mean the staff of the SEC.

     “Target Registration Date” shall have the meaning set forth in Section 2(d) hereof.

     “Trust Indenture Act” shall mean the Trust Indenture Act of 1939, as amended from time to
time.

     “Trustee” shall mean the trustee with respect to the Securities under the Indenture.

     “Underwriter” shall have the meaning set forth in Section 3(e) hereof.

4

 

     “Underwritten Offering” shall mean an offering in which Registrable Securities are sold to an
Underwriter for reoffering to the public.

     2. Registration Under the Securities Act. (a) To the extent not prohibited by any
applicable law or applicable interpretations of the Staff, the Calumet Parties shall use their
reasonable best efforts to (i) cause to be filed an Exchange Offer Registration Statement covering
an offer to the Holders to exchange all the Registrable Securities for Exchange Securities, (ii)
cause such Exchange Offer Registration Statement be declared effective by the SEC by April 21, 2012
and (iii) have such Registration Statement remain effective until 180 days after the last Exchange
Date for use by one or more Participating Broker-Dealers. The Calumet Parties shall commence the
Exchange Offer promptly after the Exchange Offer Registration Statement is declared effective by
the SEC and use their reasonable best efforts to complete the Exchange Offer not later than 60 days
after such effective date.

     The Calumet Parties shall commence the Exchange Offer by mailing the related Prospectus,
appropriate letters of transmittal and other accompanying documents to each Holder stating, in
addition to such other disclosures as are required by applicable law, substantially the following:

	(i)	 	that the Exchange Offer is being made pursuant to this Agreement and that all Registrable
Securities validly tendered and not properly withdrawn will be accepted for exchange;
	 
	(ii)	 	the dates of acceptance for exchange (which shall be a period of at least 20 Business Days
from the date such notice is mailed) (the “Exchange Dates”);
	 
	(iii)	 	that any Registrable Security not tendered will remain outstanding and continue to accrue
interest but will not retain any rights under this Agreement;
	 
	(iv)	 	that any Holder electing to have a Registrable Security exchanged pursuant to the Exchange
Offer will be required to (x) in the case a Holder electing to exchange a Registrable Security
in global form, to comply with the applicable procedures of DTC for book-entry tenders, and,
(y) in the case of a Holder electing to exchange a Registrable Security in certificated form,
to surrender such Registrable Security, together with the appropriate letters of transmittal,
to the institution and at the address (located in the Borough of Manhattan, The City of New
York) and in the manner specified in the notice, prior to the close of business on the last
Exchange Date; and
	 
	(v)	 	that any Holder will be entitled to withdraw its election, not later than the close of
business on the last Exchange Date, by (x) in the case of a Holder withdrawing its election to
exchange a Registrable Security in global form, complying with the applicable procedures of
DTC for withdrawal of tenders, and, (y) in the case of a Holder withdrawing its election to
exchange a Registrable Security in certificated form, sending to the institution and at the
address (located in the Borough of Manhattan, The City of New York) specified in the notice, a
telegram, telex, facsimile transmission or letter setting forth the name of such Holder, the
principal amount of Registrable Securities
delivered for exchange and a statement that such Holder is withdrawing its election to have
such Registrable Securities exchanged.

5

 

     As a condition to participating in the Exchange Offer, a Holder will be required to represent
to the Calumet Parties that (i) any Exchange Securities to be received by it will be acquired in
the ordinary course of its business, (ii) at the time of the commencement of the Exchange Offer it
has no arrangement or understanding with any Person to participate in the distribution (within the
meaning of the Securities Act) of the Exchange Securities in violation of the provisions of the
Securities Act, (iii) it is not an “affiliate” (within the meaning of Rule 405 under the Securities
Act) of any of the Calumet Parties and (iv) if such Holder is a broker-dealer that will receive
Exchange Securities for its own account in exchange for Registrable Securities that were acquired
as a result of market-making or other trading activities, then such Holder will deliver a
Prospectus (or, to the extent permitted by law, make available a Prospectus to purchasers) in
connection with any resale of such Exchange Securities.

     As soon as practicable after the last Exchange Date, the Calumet Parties shall:

	(i)	 	accept for exchange Registrable Securities or portions thereof validly tendered and not
properly withdrawn pursuant to the Exchange Offer; and
	 
	(ii)	 	deliver, or cause to be delivered, to the Trustee for cancellation all Registrable Securities
or portions thereof so accepted for exchange by the Issuers and issue, and cause the Trustee
to promptly authenticate and deliver to each Holder, Exchange Securities equal in principal
amount to the principal amount of the Registrable Securities surrendered by such Holder.

     The Calumet Parties shall use their reasonable best efforts to complete the Exchange Offer as
provided above and shall comply with the applicable requirements of the Securities Act, the
Exchange Act and other applicable laws and regulations in connection with the Exchange Offer. The
Exchange Offer shall not be subject to any conditions, other than that the Exchange Offer does not
violate any applicable law or applicable interpretations of the Staff.

     (b) In the event that (i) the Calumet Parties determine that the Exchange Offer Registration
provided for in Section 2(a) above is not available or may not be completed as soon as practicable
after the last Exchange Date because it would violate any applicable law or applicable
interpretations of the Staff, (ii) the Exchange Offer is not for any other reason completed by
April 21, 2012, or (iii) any Initial Purchaser shall so request (a “Shelf Request”) in connection
with any offer or sale of Registrable Securities that are ineligible to be exchanged in the
Exchange Offer, the Calumet Parties shall use their reasonable best efforts to cause to be filed as
soon as practicable after such determination, date or Shelf Request, as the case may be, a Shelf
Registration Statement providing for the sale of all the Registrable Securities by the Holders
thereof and to cause such Shelf Registration Statement to be declared effective by the SEC.

     In the event that the Calumet Parties are required to file a Shelf Registration Statement
pursuant to clause (iii) of the preceding sentence, the Calumet Parties shall use their reasonable
best efforts to file and have declared effective by the SEC both an Exchange Offer Registration
Statement pursuant to Section 2(a) with respect to all Registrable Securities and a Shelf
Registration Statement (which may be a combined Registration Statement with the Exchange

6

 

Offer Registration Statement) with respect to offers and sales of Registrable Securities held by the
Initial Purchasers after completion of the Exchange Offer.

     The Calumet Parties agree to use their reasonable best efforts to keep the Shelf Registration
Statement continuously effective for one year or such shorter period that will terminate when all
the Registrable Securities covered by the Shelf Registration Statement have been sold pursuant to
the Shelf Registration Statement (the “Shelf Effectiveness Period”). The Calumet Parties further
agree to supplement or amend the Shelf Registration Statement and the related Prospectus if
required by the rules, regulations or instructions applicable to the registration form used by the
Calumet Parties for such Shelf Registration Statement or by the Securities Act or by any other
rules and regulations thereunder for shelf registration or if reasonably requested by a Holder of
Registrable Securities with respect to information relating to such Holder, and to use their
reasonable best efforts to cause any such amendment to be declared effective, if required, and such
Shelf Registration Statement and Prospectus to become usable as soon as thereafter practicable.
The Calumet Parties agree to furnish to the Holders of Registrable Securities copies of any such
supplement or amendment promptly after its being used or filed with the SEC.

     (c) The Calumet Parties shall pay all Registration Expenses in connection with any
registration pursuant to Section 2(a) or Section 2(b) hereof. Each Holder shall pay all
underwriting discounts and commissions, brokerage commissions and transfer taxes, if any, relating
to the sale or disposition of such Holder’s Registrable Securities pursuant to the Shelf
Registration Statement.

     (d) An Exchange Offer Registration Statement pursuant to Section 2(a) or a Shelf Registration
Statement pursuant to Section 2(b) hereof will not be deemed to have become effective unless it has
been declared effective by the SEC.

     In the event that (i) either the Exchange Offer is not completed or the Shelf Registration
Statement, if required pursuant to Section 2(b)(i) or 2(b)(ii) hereof, is not declared effective on
or prior to April 21, 2012 (the “Target Registration Date”), or (ii) the Company receives a
Shelf Request pursuant to Section 2(b)(iii), and the Shelf Registration Statement required to be
filed thereby is not declared effective by the SEC by the later of (x) February 19, 2012 or (y) 90
days after the delivery of such Shelf Request (such later date, the “Shelf Additional Interest
Date”), then the interest rate on the Registrable Securities will be increased by (A) 0.25% per
annum for the first 90-day period immediately following the Target Registration Date or the Shelf
Additional Interest Date, as applicable, and (B) an additional 0.25% per annum with respect to each
subsequent 90-day period, in each case until the Exchange Offer is completed or the Shelf
Registration Statement, if required hereby, is declared effective by the SEC or the Securities no
longer qualify as Registrable Securities, up to a maximum of 1.00% per annum of additional
interest.

     If the Shelf Registration Statement, if required hereby, has been declared effective by the
SEC and thereafter either ceases to be effective or the Prospectus contained therein ceases to be
usable at any time during the Shelf Effectiveness Period, and such failure to remain effective or
usable exists for more than 45 days (whether or not consecutive) in any 12-month period, then
the interest rate on the Registrable Securities will be increased by (i) 0.25% per annum

7

 

commencing on the 45th day in such 12-month period and (ii) an additional 0.25% per annum with respect to each
subsequent 90-day period (whether or not consecutive) and ending on such date that the Shelf
Registration Statement has again been declared effective by the SEC or the Prospectus again becomes
usable, up to a maximum of 1.00% per annum of additional interest.

     (e) Any additional interest paid in accordance with this Section 2 shall be liquidated damages
and shall be the sole and exclusive remedy available to Holders due a failure by the Calumet
Parties to comply with their obligations under Section 2(a) and Section 2(b).

     3. Registration Procedures. (a) In connection with their obligations pursuant to
Section 2(a) and Section 2(b) hereof, the Calumet Parties shall as expeditiously as possible:

     (i) prepare and file with the SEC a Registration Statement on the appropriate form under the
Securities Act, which form (x) shall be selected by the Calumet Parties, (y) shall, in the case of
a Shelf Registration, be available for the sale of the Registrable Securities by the Holders
thereof and (z) shall comply as to form in all material respects with the requirements of the
applicable form and include all financial statements required by the SEC to be filed therewith; and
use their reasonable best efforts to cause such Registration Statement to be declared effective by
the SEC and remain effective for the applicable period in accordance with Section 2 hereof;

     (ii) prepare and file with the SEC such amendments and post-effective amendments to each
Registration Statement as may be necessary to keep such Registration Statement effective for the
applicable period in accordance with Section 2 hereof and cause each Prospectus to be supplemented
by any required prospectus supplement and, as so supplemented, to be filed pursuant to Rule 424
under the Securities Act; and keep each Prospectus current during the period described in Section
4(3) of and Rule 174 under the Securities Act that is applicable to transactions by brokers or
dealers with respect to the Registrable Securities or Exchange Securities;

     (iii) in the case of a Shelf Registration, furnish to each Holder of Registrable Securities,
to counsel for the Initial Purchasers, to counsel for such Holders and to each Underwriter of an
Underwritten Offering of Registrable Securities, if any, without charge, as many copies of each
Prospectus or preliminary prospectus, and any amendment or supplement thereto, as such Holder,
counsel or Underwriter may reasonably request in order to facilitate the sale or other disposition
of the Registrable Securities thereunder; and the Calumet Parties consent to the use of such
Prospectus, preliminary prospectus and any amendment or supplement thereto in accordance with
applicable law by each of the Holders of Registrable Securities and any such Underwriters in
connection with the offering and sale of the Registrable Securities covered by and in the manner
described in such Prospectus, preliminary prospectus or any amendment or supplement thereto in
accordance with applicable law;

     (iv) use their reasonable best efforts to register or qualify the Registrable Securities under
all applicable state securities or blue sky laws of such jurisdictions in the United States as any
Holder of Registrable Securities covered by a Registration Statement shall reasonably request in
writing by the time the applicable Registration Statement is declared effective by the
SEC; cooperate with such Holders in connection with any filings required to be made with the
Financial Industry Regulatory Authority, Inc.; and do any and all other acts and things that may

8

 

be reasonably necessary or advisable to enable each Holder to complete the disposition in each such
jurisdiction of the Registrable Securities owned by such Holder; provided that none of the
Calumet Parties shall be required to (1) qualify as a foreign corporation or other entity or as a
dealer in securities in any such jurisdiction where it would not otherwise be required to so
qualify, (2) file any general consent to service of process in any such jurisdiction or (3) subject
itself to taxation in any such jurisdiction if it is not so subject;

     (v) notify counsel for the Initial Purchasers and, in the case of a Shelf Registration, notify
each Holder of Registrable Securities and counsel for such Holders promptly and, if requested by
any such Holder or counsel, confirm such advice in writing (1) when a Registration Statement has
become effective, when any post-effective amendment thereto has been filed and becomes effective
and when any amendment or supplement to the Prospectus has been filed, (2) of any request by the
SEC or any state securities authority for amendments and supplements to a Registration Statement or
Prospectus or for additional information after the Registration Statement has become effective, (3)
of the issuance by the SEC or any state securities authority of any stop order suspending the
effectiveness of a Registration Statement or the initiation of any proceedings for that purpose,
including the receipt by the Calumet Parties of any notice of objection of the SEC to the use of a
Shelf Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2)
under the Securities Act, (4) if, between the applicable effective date of a Shelf Registration
Statement and the closing of any sale of Registrable Securities covered thereby, the
representations and warranties of any of the Calumet Parties contained in any underwriting
agreement, securities sales agreement or other similar agreement, if any, relating to an offering
of such Registrable Securities cease to be true and correct in all material respects or if any of
the Calumet Parties receives any notification with respect to the suspension of the qualification
of the Registrable Securities for sale in any jurisdiction or the initiation of any proceeding for
such purpose, (5) of the happening of any event during the period a Registration Statement is
effective that makes any statement made in such Registration Statement or the related Prospectus
untrue in any material respect or that requires the making of any changes in such Registration
Statement or Prospectus in order to make the statements therein not misleading and (6) of any
determination by any of the Calumet Parties that a post-effective amendment to a Registration
Statement or any amendment or supplement to the Prospectus would be appropriate;

     (vi) use their reasonable best efforts to obtain the withdrawal of any order suspending the
effectiveness of a Registration Statement or, in the case of a Shelf Registration, the resolution
of any objection of the SEC pursuant to Rule 401(g)(2), including by filing an amendment to such
Shelf Registration Statement on the proper form, at the earliest possible moment and provide
immediate notice to each Holder of the withdrawal of any such order or such resolution;

     (vii) in the case of a Shelf Registration, furnish to each Holder of Registrable Securities,
without charge, at least one conformed copy of each Registration Statement and any post-effective
amendment thereto (without any documents incorporated therein by reference or exhibits thereto,
unless requested); provided, however, that any such document available on the SEC’s EDGAR database
shall satisfy such obligation;

     (viii) in the case of a Shelf Registration, cooperate with the Holders of Registrable
Securities in certificated form to facilitate the timely preparation and delivery of certificates

9

 

representing Registrable Securities to be sold and not bearing any restrictive legends and enable
such Registrable Securities to be issued in such denominations and registered in such names
(consistent with the provisions of the Indenture) as such Holders may reasonably request at least
two Business Days prior to the closing of any sale of Registrable Securities in certificated form;

     (ix) in the case of a Shelf Registration, upon the occurrence of any event contemplated by
Section 3(a)(v)(5) hereof, use their reasonable best efforts to prepare and file with the SEC a
supplement or post-effective amendment to such Shelf Registration Statement or the related
Prospectus or any document incorporated therein by reference or file any other required document so
that, as thereafter delivered (or, to the extent permitted by law, made available) to purchasers of
the Registrable Securities, such Prospectus will not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading; and the Calumet Parties shall notify the
Holders of Registrable Securities to suspend use of the Prospectus as promptly as practicable after
the occurrence of such an event, and such Holders hereby agree to suspend use of the Prospectus
until the Calumet Parties have amended or supplemented the Prospectus to correct such misstatement
or omission;

     (x) a reasonable time prior to the filing of any Registration Statement, any Prospectus, any
amendment to a Registration Statement or amendment or supplement to a Prospectus or of any document
that is to be incorporated by reference into a Registration Statement or a Prospectus after initial
filing of a Registration Statement, provide copies of such document to the Initial Purchasers and
their counsel (and, in the case of a Shelf Registration Statement, to the Holders of Registrable
Securities and their counsel) and make such of the representatives of the Calumet Parties as shall
be reasonably requested by the Initial Purchasers or their counsel (and, in the case of a Shelf
Registration Statement, the Holders of Registrable Securities or their counsel) available for
discussion of such document; and the Calumet Parties shall not, at any time after initial filing of
a Registration Statement, use or file any Prospectus, any amendment of or supplement to a
Registration Statement or a Prospectus, or any document that is to be incorporated by reference
into a Registration Statement or a Prospectus, of which the Initial Purchasers and their counsel
(and, in the case of a Shelf Registration Statement, the Holders of Registrable Securities and
their counsel) shall not have previously been advised and furnished a copy or to which the Initial
Purchasers or their counsel (and, in the case of a Shelf Registration Statement, the Holders of
Registrable Securities or their counsel) shall reasonably object; provided, that this clause shall
not apply to any filing by the Partnership of any Annual Report on Form 10-K, Quarterly Report on
Form 10-Q or Current Report on Form 8-K with respect to matters unrelated to the Securities and the
offering or exchange therefor;

     (xi) obtain a CUSIP number for all Exchange Securities or Registrable Securities, as the case
may be, not later than the initial effective date of a Registration Statement;

     (xii) cause the Indenture to be qualified under the Trust Indenture Act in connection with the
registration of the Exchange Securities or Registrable Securities, as the case may be; cooperate
with the Trustee and the Holders to effect such changes to the Indenture as may be required for the
Indenture to be so qualified in accordance with the terms of the Trust Indenture
Act; and execute, and use their reasonable best efforts to cause the Trustee to execute, all

10

 

documents as may be required to effect such changes and all other forms and documents required to
be filed with the SEC to enable the Indenture to be so qualified in a timely manner;

     (xiii) in the case of a Shelf Registration, make available for inspection by a representative
(an “Inspector”) of the Holders of the Registrable Securities, any Underwriter participating in any
disposition pursuant to such Shelf Registration Statement, any attorneys and accountants designated
by a majority of the Holders of Registrable Securities to be included in such Shelf Registration
and any attorneys and accountants designated by such Underwriter, at reasonable times and in a
reasonable manner, all pertinent financial and other records, documents and properties of the
Calumet Parties and their subsidiaries, and cause the respective officers, directors and employees
of the Calumet Parties to supply all information reasonably requested by any such Inspector,
Underwriter, attorney or accountant in connection with a Shelf Registration Statement, in each case
as is customary for “due diligence” examinations in the context of underwritten offerings;
provided that if any such information is identified by the Calumet Parties as being
confidential or proprietary, each Person receiving such information shall take such actions as are
reasonably necessary to protect the confidentiality of such information to the extent such action
is otherwise not inconsistent with, an impairment of or in derogation of the rights and interests
of any Inspector, Holder or Underwriter;

     (xiv) in the case of a Shelf Registration, use their reasonable best efforts to cause all
Registrable Securities to be listed on any securities exchange or any automated quotation system on
which similar securities issued or guaranteed by the Calumet Parties are then listed if requested
by the Majority Holders, to the extent such Registrable Securities satisfy applicable listing
requirements;

     (xv) if reasonably requested by any Holder of Registrable Securities covered by a Shelf
Registration Statement, promptly include in a Prospectus supplement or post-effective amendment
such information with respect to such Holder as such Holder reasonably requests to be included
therein and make all required filings of such Prospectus supplement or such post-effective
amendment as soon as the Calumet Parties have received notification of the matters to be so
included in such filing;

     (xvi) in the case of a Shelf Registration, enter into such customary agreements and take all
such other actions in connection therewith (including those requested by the Holders of a majority
in principal amount of the Registrable Securities covered by the Shelf Registration Statement) in
order to expedite or facilitate the disposition of such Registrable Securities including, but not
limited to, an Underwritten Offering and in such connection, (1) to the extent possible, make such
representations and warranties to the Holders and any Underwriters of such Registrable Securities
with respect to the business of the Calumet Parties and their subsidiaries and the Registration
Statement, Prospectus and documents incorporated by reference or deemed incorporated by reference,
if any, in each case, in form, substance and scope as are customarily made by issuers to
underwriters in underwritten offerings and confirm the same if and when requested, (2) obtain
opinions of counsel to the Calumet Parties (which counsel and opinions, in form, scope and
substance, shall be reasonably satisfactory to the Holders and such Underwriters and their
respective counsel) addressed to each selling Holder (to the extent such Holder has advised the
Issuers that such Holder may have a “due diligence” defense under Section 11 of the
Securities Act) and Underwriter of Registrable Securities, covering the matters customarily

11

 

covered in opinions requested in underwritten offerings, (3) obtain “comfort” letters from the
independent registered public accounting firm of the Calumet Parties (and, if necessary, any other
certified public accountant of any subsidiary of the Calumet Parties, or of any business acquired
by the Calumet Parties for which financial statements and financial data are or are required to be
included in the Registration Statement) addressed to each selling Holder (to the extent permitted
by applicable professional standards) and Underwriter of Registrable Securities, such letters to be
in customary form and covering matters of the type customarily covered in “comfort” letters in
connection with underwritten offerings, including but not limited to financial information
contained in any preliminary prospectus or Prospectus and (4) deliver such documents and
certificates as may be reasonably requested by the Holders of a majority in principal amount of the
Registrable Securities being sold or the Underwriters, and which are customarily delivered in
underwritten offerings, to evidence the continued validity of the representations and warranties of
the Calumet Parties made pursuant to clause (1) above and to evidence compliance with any customary
conditions contained in an underwriting agreement; and

     (xvii) so long as any Registrable Securities remain outstanding, cause each Additional
Guarantor upon the creation or acquisition by the Issuers of such Additional Guarantor, to execute
a joinder agreement in the form attached hereto as Annex A and to deliver such joinder agreement,
together with an opinion of counsel as to the enforceability thereof against such entity, to the
Initial Purchasers no later than five Business Days following the execution thereof.

     (b) In the case of a Shelf Registration Statement, the Issuers may require each Holder of
Registrable Securities to furnish to the Issuers such information regarding such Holder and the
proposed disposition by such Holder of such Registrable Securities as the Calumet Parties may from
time to time reasonably request in writing.

     (c) In the case of a Shelf Registration Statement, each Holder of Registrable Securities
covered in such Shelf Registration Statement agrees that, upon receipt of any notice from the
Calumet Parties of the happening of any event of the kind described in Section 3(a)(v)(3) or
3(a)(v)(5) hereof, such Holder will forthwith discontinue disposition of Registrable Securities
pursuant to the Shelf Registration Statement until such Holder’s receipt of the copies of the
supplemented or amended Prospectus contemplated by Section 3(a)(ix) hereof and, if so directed by
the Calumet Parties, such Holder will deliver to the Calumet Parties all copies in its possession,
other than permanent file copies then in such Holder’s possession, of the Prospectus covering such
Registrable Securities that is current at the time of receipt of such notice.

     (d) If the Calumet Parties shall give any notice to suspend the disposition of Registrable
Securities pursuant to a Registration Statement, the Calumet Parties shall extend the period during
which such Registration Statement shall be maintained effective pursuant to this Agreement by the
number of days during the period from and including the date of the giving of such notice to and
including the date when the Holders of such Registrable Securities shall have received copies of
the supplemented or amended Prospectus necessary to resume such dispositions. The Calumet Parties
may give any such notice only twice during any 365-day period and any such suspensions shall not
exceed 30 days for each suspension and there shall not be more than two suspensions in effect
during any 365-day period.

12

 

     (e) The Holders of Registrable Securities covered by a Shelf Registration Statement who desire
to do so may sell such Registrable Securities in an Underwritten Offering. In any such
Underwritten Offering, the investment bank or investment banks and manager or managers (each an
“Underwriter”) that will administer the offering will be selected by the Holders of a majority in
principal amount of the Registrable Securities included in such offering; provided that, with
respect to any Underwriter other than Merrill Lynch, such selections shall be subject to the
approval of the Partnership, which approval shall not be unreasonably withheld.

     4. Participation of Broker-Dealers in Exchange Offer. (a) The Staff has taken the
position that any broker-dealer that receives Exchange Securities for its own account in the
Exchange Offer in exchange for Securities that were acquired by such broker-dealer as a result of
market-making or other trading activities (a “Participating Broker-Dealer”) may be deemed to be an
“underwriter” within the meaning of the Securities Act and must deliver a prospectus meeting the
requirements of the Securities Act in connection with any resale of such Exchange Securities.

     The Calumet Parties understand that it is the Staff’s position that if the Prospectus
contained in the Exchange Offer Registration Statement includes a plan of distribution containing a
statement to the above effect and the means by which Participating Broker-Dealers may resell the
Exchange Securities, without naming the Participating Broker-Dealers or specifying the amount of
Exchange Securities owned by them, such Prospectus may be delivered by Participating Broker-Dealers
(or, to the extent permitted by law, made available to purchasers) to satisfy their prospectus
delivery obligation under the Securities Act in connection with resales of Exchange Securities for
their own accounts, so long as the Prospectus otherwise meets the requirements of the Securities
Act.

     (b) In light of the above, and notwithstanding the other provisions of this Agreement, the
Calumet Parties agree to amend or supplement the Prospectus contained in the Exchange Offer
Registration Statement for a period of up to 180 days after the last Exchange Date (as such period
may be extended pursuant to Section 3(d) of this Agreement), in order to expedite or facilitate the
disposition of any Exchange Securities by Participating Broker-Dealers consistent with the
positions of the Staff recited in Section 4(a) above. The Calumet Parties further agree that
Participating Broker-Dealers shall be authorized to deliver such Prospectus (or, to the extent
permitted by law, make available) during such period in connection with the resales contemplated by
this Section 4.

     (c) The Initial Purchasers shall have no liability to any of the Calumet Parties or any Holder
with respect to any request that they may make pursuant to Section 4(b) above.

     5. Indemnification and Contribution. (a) Each of the Calumet Parties, jointly and
severally, agree to indemnify and hold harmless each Initial Purchaser and each Holder, their
respective affiliates, directors and officers and each Person, if any, who controls any Initial
Purchaser or any Holder within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act, from and against any and all losses, claims, damages and liabilities (including,
without limitation, legal fees and other expenses incurred in connection with any suit, action or
proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that
arise out of, or are based upon, (1) any untrue statement or alleged untrue statement of a material

13

 

fact contained in any Registration Statement or any omission or alleged omission to state
therein a material fact required to be stated therein or necessary in order to make the statements
therein not misleading, or (2) any untrue statement or alleged untrue statement of a material fact
contained in any Prospectus, any free writing prospectus (as defined in Rule 405 under the
Securities Act (“Free Writing Prospectus”) used in violation of this Agreement or any “issuer
information” (“Issuer Information”) filed or required to be filed pursuant to Rule 433(d) under the
Securities Act, or any omission or alleged omission to state therein a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made,
not misleading, in each case except insofar as such losses, claims, damages or liabilities arise
out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission
made in reliance upon and in conformity with any information relating to any Initial Purchaser or
information relating to any Holder furnished to the Issuers in writing through Merrill Lynch or any
selling Holder, respectively, expressly for use therein. In connection with any Underwritten
Offering permitted by Section 3, the Calumet Parties, jointly and severally, will also indemnify
the Underwriters, if any, selling brokers, dealers and similar securities industry professionals
participating in the distribution, their respective affiliates and each Person who controls such
Persons (within the meaning of the Securities Act and the Exchange Act) to the same extent as
provided above with respect to the indemnification of the Holders, if requested in connection with
any Registration Statement, any Prospectus, any Free Writing Prospectus or any Issuer Information.

     (b) Each Holder agrees, severally and not jointly, to indemnify and hold harmless the Calumet
Parties, the Initial Purchasers and the other selling Holders, the directors of the Calumet
Parties, each officer of the Calumet Parties who signed the Registration Statement and each Person,
if any, who controls the Calumet Parties, any Initial Purchaser and any other selling Holder within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same
extent as the indemnity set forth in paragraph (a) above, but only with respect to any losses,
claims, damages or liabilities that arise out of, or are based upon, any untrue statement or
omission or alleged untrue statement or omission made in reliance upon and in conformity with any
information relating to such Holder furnished to the Calumet Parties in writing by such Holder
expressly for use in any Registration Statement and any Prospectus.

     (c) If any suit, action, proceeding (including any governmental or regulatory investigation),
claim or demand shall be brought or asserted against any Person in respect of which indemnification
may be sought pursuant to either paragraph (a) or (b) above, such Person (the “Indemnified Person”)
shall promptly notify the Person against whom such indemnification may be sought (the “Indemnifying
Person”) in writing; provided that the failure to notify the Indemnifying Person shall not
relieve it from any liability that it may have under this Section 5 except to the extent that it
has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such
failure; and provided, further, that the failure to notify the Indemnifying Person
shall not relieve it from any liability that it may have to an Indemnified Person otherwise than
under this Section 5. If any such proceeding shall be brought or asserted against an Indemnified
Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall
retain counsel reasonably satisfactory to the Indemnified Person to represent the Indemnified
Person and any others entitled to indemnification pursuant to this Section 5 that the Indemnifying
Person may designate in such proceeding and shall pay the fees and expenses of such proceeding and
shall pay the fees and expenses of such counsel related to such proceeding,

14

 

as incurred. In any such proceeding, any Indemnified Person shall have the right to retain
its own counsel, but the fees and expenses of such counsel shall be at the expense of such
Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have
mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time
to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person
shall have reasonably concluded that there may be legal defenses available to it that are different
from or in addition to those available to the Indemnifying Person; or (iv) the named parties in any
such proceeding (including any impleaded parties) include both the Indemnifying Person and the
Indemnified Person and representation of both parties by the same counsel would be inappropriate
due to actual or potential differing interests between them. It is understood and agreed that the
Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same
jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to
any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be
reimbursed as they are incurred. Any such separate firm (x) for any Initial Purchaser, its
affiliates, directors and officers and any control Persons of such Initial Purchaser shall be
designated in writing by Merrill Lynch, (y) for any Holder, its directors and officers and any
control Persons of such Holder shall be designated in writing by the Majority Holders and (z) in
all other cases shall be designated in writing by the Partnership. The Indemnifying Person shall
not be liable for any settlement of any proceeding effected without its written consent, but if
settled with such consent or if there be a final judgment for the plaintiff, the Indemnifying
Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason
of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an
Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified
Person for fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person
shall be liable for any settlement of any proceeding effected without its written consent if (i)
such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such
request and (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in
accordance with such request prior to the date of such settlement. No Indemnifying Person shall,
without the written consent of the Indemnified Person, effect any settlement of any pending or
threatened proceeding in respect of which any Indemnified Person is or could have been a party and
indemnification could have been sought hereunder by such Indemnified Person, unless such settlement
(A) includes an unconditional release of such Indemnified Person, in form and substance reasonably
satisfactory to such Indemnified Person, from all liability on claims that are the subject matter
of such proceeding and (B) does not include any statement as to or any admission of fault,
culpability or a failure to act by or on behalf of any Indemnified Person.

     (d) If the indemnification provided for in paragraphs (a) and (b) above is unavailable to an
Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities
referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying
such Indemnified Person thereunder, shall contribute to the amount paid or payable by such
Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such
proportion as is appropriate to reflect the relative benefits received by the Calumet Parties from
the offering of the Securities and the Exchange Securities, on the one hand, and by the Holders
from receiving Securities or Exchange Securities registered under the Securities Act, on the other
hand, or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)
but also the relative fault of the Calumet Parties on the one hand and the Holders on the other in

15

 

connection with the statements or omissions that resulted in such losses, claims, damages or
liabilities, as well as any other relevant equitable considerations. The relative fault of the
Calumet Parties on the one hand and the Holders on the other shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information supplied by the
Calumet Parties or by the Holders and the parties’ relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.

     (e) The Calumet Parties and the Holders agree that it would not be just and equitable if
contribution pursuant to this Section 5 were determined by pro rata allocation
(even if the Holders were treated as one entity for such purpose) or by any other method of
allocation that does not take account of the equitable considerations referred to in paragraph (d)
above. The amount paid or payable by an Indemnified Person as a result of the losses, claims,
damages and liabilities referred to in paragraph (d) above shall be deemed to include, subject to
the limitations set forth above, any legal or other expenses incurred by such Indemnified Person in
connection with any such action or claim. Notwithstanding the provisions of this Section 5, in no
event shall a Holder be required to contribute any amount in excess of the amount by which the
total price at which the Securities or Exchange Securities sold by such Holder exceeds the amount
of any damages that such Holder has otherwise been required to pay by reason of such untrue or
alleged untrue statement or omission or alleged omission. No Person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any Person who was not guilty of such fraudulent misrepresentation. The Holders’
obligations to contribute pursuant to this Section 5 are several and not joint.

     (f) The remedies provided for in this Section 5 are not exclusive and shall not limit any
rights or remedies that may otherwise be available to any Indemnified Person at law or in equity.

     (g) The indemnity and contribution provisions contained in this Section 5 shall remain
operative and in full force and effect regardless of (i) any termination of this Agreement, (ii)
any investigation made by or on behalf of the Initial Purchasers or any Holder or any Person
controlling any Initial Purchaser or any Holder, or by or on behalf of the Calumet Parties or the
officers or directors of or any Person controlling any of the Calumet Parties, (iii) acceptance of
any of the Exchange Securities and (iv) any sale of Registrable Securities pursuant to a Shelf
Registration Statement.

     6. General.

     (a) No Inconsistent Agreements. The Calumet Parties represent, warrant and agree that (i)
the rights granted to the Holders hereunder do not in any way conflict with and are not
inconsistent with the rights granted to the holders of any other outstanding securities issued or
guaranteed by any of the Calumet Parties under any other agreement and (ii) none of the Calumet
Parties has entered into, or on or after the date of this Agreement will enter into, any agreement
that is inconsistent with the rights granted to the Holders of Registrable Securities in this
Agreement or otherwise conflicts with the provisions hereof.

16

 

     (b) Amendments and Waivers. The provisions of this Agreement, including the provisions of
this sentence, may not be amended, modified or supplemented, and waivers or consents to departures
from the provisions hereof may not be given unless the Calumet Parties have obtained the written
consent of Holders of at least a majority in aggregate principal amount of the outstanding
Registrable Securities affected by such amendment, modification, supplement, waiver or consent;
provided that no amendment, modification, supplement, waiver or consent to any departure
from the provisions of Section 5 hereof shall be effective as against any Holder of Registrable
Securities unless consented to in writing by such Holder. Any amendments, modifications,
supplements, waivers or consents pursuant to this Section 6(b) shall be by a writing executed by
each of the parties hereto.

     (c) Notices. All notices and other communications provided for or permitted hereunder shall
be made in writing by hand-delivery, registered first-class mail, telex, telecopier, or any courier
guaranteeing overnight delivery (i) if to a Holder, at the most current address given by such
Holder to the Issuers by means of a notice given in accordance with the provisions of this Section
6(c), which address initially is, with respect to the Initial Purchasers, the address set forth in
the Purchase Agreement; (ii) if to the Calumet Parties, initially at the Issuers’ address set forth
in the Purchase Agreement and thereafter at such other address, notice of which is given in
accordance with the provisions of this Section 6(c); and (iii) to such other persons at their
respective addresses as provided in the Purchase Agreement and thereafter at such other address,
notice of which is given in accordance with the provisions of this Section 6(c). All such notices
and communications shall be deemed to have been duly given: at the time delivered by hand, if
personally delivered; five Business Days after being deposited in the mail, postage prepaid, if
mailed; when receipt is acknowledged, if telecopied; and on the next Business Day if timely
delivered to an air courier guaranteeing overnight delivery. Copies of all such notices, demands
or other communications shall be concurrently delivered by the Person giving the same to the
Trustee, at the address specified in the Indenture.

     (d) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon
the successors, assigns and transferees of each of the parties, including, without limitation and
without the need for an express assignment, subsequent Holders; provided that nothing
herein shall be deemed to permit any assignment, transfer or other disposition of Registrable
Securities in violation of the terms of the Purchase Agreement or the Indenture. If any transferee
of any Holder shall acquire Registrable Securities in any manner, whether by operation of law or
otherwise, such Registrable Securities shall be held subject to all the terms of this Agreement,
and by taking and holding such Registrable Securities such Person shall be conclusively deemed to
have agreed to be bound by and to perform all of the terms and provisions of this Agreement and
such Person shall be entitled to receive the benefits hereof. The Initial Purchasers (in their
capacity as Initial Purchasers) shall have no liability or obligation to the Calumet Parties with
respect to any failure by a Holder to comply with, or any breach by any Holder of, any of the
obligations of such Holder under this Agreement.

     (e) Third Party Beneficiaries. Each Holder shall be a third party beneficiary to the
agreements made hereunder between the Calumet Parties, on the one hand, and the Initial Purchasers,
on the other hand, and shall have the right to enforce such agreements directly to the extent it
deems such enforcement necessary or advisable to protect its rights or the rights of other Holders
hereunder.

17

 

     (f) Counterparts. This Agreement may be executed in any number of counterparts and by the
parties hereto in separate counterparts, each of which when so executed shall be deemed to be an
original and all of which taken together shall constitute one and the same agreement.

     (g) Headings. The headings in this Agreement are for convenience of reference only, are not a
part of this Agreement and shall not limit or otherwise affect the meaning hereof.

     (h) Governing Law. This Agreement shall be governed by and construed in accordance with the
laws of the State of New York.

     (i) Entire Agreement; Severability. This Agreement contains the entire agreement between the
parties relating to the subject matter hereof and supersedes all oral statements and prior writings
with respect thereto. If any term, provision, covenant or restriction contained in this Agreement
is held by a court of competent jurisdiction to be invalid, void or unenforceable or against public
policy, the remainder of the terms, provisions, covenants and restrictions contained herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated. The
Calumet Parties and the Initial Purchasers shall endeavor in good faith negotiations to replace the
invalid, void or unenforceable provisions with valid provisions the economic effect of which comes
as close as possible to that of the invalid, void or unenforceable provisions.

[Signature pages follow.]

18

 

     IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
above written.

	 	 	 	 	 
	 	CALUMET SPECIALTY PRODUCTS PARTNERS, L.P.

 	 
	 	By:  	Calumet GP, LLC, its general partner
 	 
	 	 	 	 

					
	 	By:  	/s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President, Chief Financial

Officer and Secretary 	 
	 

	 	 	 	 	 
	 	CALUMET FINANCE CORP.

 	 
	 	By:  	/s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President, Chief Financial

Officer and Secretary 	 
	 

	 	 	 	 	 
	 	CALUMET OPERATING, LLC

 	 
	 	 	 

					
	 	By:  	Calumet Specialty Products Partners, L.P.,
its sole member
 	 
	 	 	 
	 	By:  	Calumet GP, LLC,

its General Partner
 	 
	 	 	 

					
	 	
 	 
	 	By:  	/s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President, Chief Financial

Officer and Secretary 	 
	 

[Signature Page to Registration Rights Agreement]

19

 

	 	 	 	 	 
	 	CALUMET LP GP, LLC

 	 
	 	 	 

					
	 	By:  	Calumet Operating, LLC,

its sole member
 	 
	 	 	 
	 	By:  	Calumet Specialty Products Partners, L.P.,

its sole member
 	 
	 	 	 
	 	By:  	Calumet GP, LLC,

its General Partner
 	 
	 	
 	 

					
	 	
 	 
	 	By:  	/s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President, Chief Financial

Officer and Secretary 	 
	 

	 	 	 	 	 
	 	CALUMET LUBRICANTS CO., LIMITED 

PARTNERSHIP

 	 
	 	 	 

					
	 	By:  	Calumet LP GP, LLC,

its general partner
 	 
	 	 	 
	 	By:  	Calumet Operating, LLC,

its sole member
 	 
	 	 	 
	 	By:  	Calumet Specialty Products Partners, L.P.,

its sole member
 	 
	 	 	 
	 	By:  	Calumet GP, LLC,

its General Partner
 	 
	 	 	 

					
	 	
 	 
	 	By:  	/s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President, Chief Financial

Officer and Secretary 	 
	 

	 	 	 	 	 
	 	CALUMET SALES COMPANY INCORPORATED

 	 
	 	 	 

					
	 	By:  	                /s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President, Chief Financial

Officer and Secretary 	 
	 

[Signature Page to Registration Rights Agreement]

20

 

	 	 	 	 	 
	 	CALUMET SHREVEPORT, LLC

 	 
	 	 	 

					
	 	By:  	Calumet Lubricants Co., Limited Partnership,

its sole member
 	 
	 	 	 
	 	By:  	Calumet LP GP, LLC,

its general partner
 	 
	 	 	 
	 	By:  	Calumet Operating, LLC,

its sole member
 	 
	 	 	 
	 	By:  	Calumet Specialty Products Partners, L.P.,

its sole member
 	 
	 	 	 
	 	By:  	Calumet GP, LLC,

its General Partner
 	 
	 	 	 

					
	 	
 	 
	 	By:  	/s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President, Chief Financial

Officer and Secretary 	 
	 

	 	 	 	 	 
	 	CALUMET SHREVEPORT FUELS, LLC

CALUMET SHREVEPORT LUBRICANTS & WAXES, LLC

 	 
	 	 	 

					

	 	By:  	
Calumet Shreveport, LLC,

its sole member
 	 
	 	 	 
	 	By:  	Calumet Lubricants Co., Limited Partnership,

its sole member 	 
	 	 	 
	 	By:  	Calumet LP GP, LLC,

its general partner
 	 
	 	 	 
	 	By:  	Calumet Operating, LLC,

its sole member
 	 
	 	 	 
	 	By:  	Calumet Specialty Products Partners, L.P.,

its sole member
 	 
	 	 	 
	 	By:  	Calumet GP, LLC,

its General Partner
 	 
	 	 	 

					
	 	
 	 
	 	By:  	                      /s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President, Chief Financial

Officer and Secretary 	 
	 

[Signature Page to Registration Rights Agreement]

21

 

	 	 	 	 	 
	 	CALUMET PENRECO, LLC

 	 
	 	 	 

					
	 	By:  	
Calumet Lubricants Co., Limited Partnership,

its sole member
 	 
	 	 	 
	 	By:  	Calumet LP GP, LLC,

its general partner
 	 
	 	 	 
	 	By:  	Calumet Operating, LLC,

its sole member
 	 
	 	 	 
	 	By:  	Calumet Specialty Products Partners, L.P.,

its sole member
 	 
	 	 	 
	 	By:  	Calumet GP, LLC,

its general partner
 	 
	 	 	 

					
	 	
 	 
	 	By:  	/s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President, Chief Financial
Officer and Secretary 	 
	 

	 	 	 	 	 
	 	CALUMET SUPERIOR, LLC

 	 
	 	 	 

					
	 	By:  	
Calumet Lubricants Co., Limited Partnership,

its sole member
 	 
	 	 	 
	 	By:  	Calumet LP GP, LLC,

its general partner
 	 
	 	 	 
	 	By:  	Calumet Operating, LLC,

its sole member
 	 
	 	 	 
	 	By:  	Calumet Specialty Products Partners, L.P.,

its sole member
 	 
	 	 	 
	 	By:  	Calumet GP, LLC,

its General Partner
 	 
	 	 	 

					
	 	
 	 
	 	By:  	/s/ R. Patrick Murray, II
 	 
	 	 	Name:  	R. Patrick Murray, II 	 
	 	 	Title:  	Vice President, Chief Financial

Officer and Secretary 	 
	 

[Signature Page to Registration Rights Agreement]

22

 

Confirmed and accepted as of the date first above written:

MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED

BARCLAYS CAPITAL INC.

For themselves and on behalf of the

several Initial Purchasers

 

					
	 	
MERRILL LYNCH, PIERCE, FENNER & SMITH

INCORPORATED

 	 
	 	By:  	/s/ Mark Sooby
 	 
	 	 	Name:  	Mark Sooby 	 
	 	 	Title:  	Managing Director 	 
	 

					
	 	

BARCLAYS CAPITAL INC.

 	 
	 	By:  	/s/ Authorized Signatory
 	 
	 	 	Name:  	Authorized Signatory 	 
	 	 	Title:  	Director 	 
	 

[Signature Page to Registration Rights Agreement]

23

 

Annex A

Form of Joinder Agreement

     The undersigned hereby absolutely, unconditionally and irrevocably agrees as a Guarantor (as
defined in the Registration Rights Agreement, dated as of September [•], 2011 by and among Calumet
Specialty Products Partners, L.P., a Delaware limited partnership (the “Partnership”), Calumet
Finance Corp., a Delaware corporation, the guarantors party thereto, and Merrill Lynch, Pierce,
Fenner & Smith, Incorporated, on behalf of itself and the other Initial Purchasers) to be bound by
the terms and provisions of such Registration Rights Agreement.

     IN WITNESS WHEREOF, the undersigned has executed this agreement as of ______________, 20_.

	 	 	 	 	 
	 	[NAME]

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

24exv10w1

Exhibit 10.1

Text marked by [* * *] has been omitted pursuant to a Request for Confidential Treatment

and was filed separately with the Securities and Exchange Commission

LICENSE AGREEMENT

AMONG

THE HENRY M. JACKSON FOUNDATION FOR THE

ADVANCEMENT OF MILITARY MEDICINE, INC.

AND

THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM and

THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER

AND

RXI PHARMACEUTICALS CORPORATION

     THIS EXCLUSIVE LICENSE AGREEMENT is entered into as of the date of the last signature on the
signature page of this document (the “Effective Date”), by and among The Henry M. Jackson
Foundation for the Advancement of Military Medicine, Inc., a tax-exempt corporation organized under
the laws of the State of Maryland and having its principal offices at 6720-A Rockledge Drive, Suite
100 Bethesda, Maryland 20817 (the “Foundation”), The Board of Regents (“Board”) of The University
of Texas System (“System”), an agency of the State of Texas, whose address is 201 West 7th Street,
Austin, Texas 78701, on behalf of The University of Texas M. D. Anderson Cancer Center (“UTMDACC”),
a member institution of System, and RXi Pharmaceuticals Corporation, a corporation organized under
the laws of the State of Delaware and having its principal offices at 60 Prescott Street,
Worcester, Massachusetts 01605 (“Licensee”). Board, UTMDACC and the Foundation sometimes are
referred to collectively as “Owners.” The Foundation, Board, UTMDACC, and Licensee sometimes are
referred to collectively herein as the “Parties” and individually as a “Party.”

     WHEREAS the Foundation and the Uniformed Services University of the Health Sciences, an
institution of higher learning within the Department of Defense, an agency of the United States
Government, located at 4301 Jones Bridge Road, Bethesda, Maryland 20814 (“USU”) have agreed to
collaborate in the development and commercialization of inventions, patents, trade secrets, and
other intellectual property rights; and

     WHEREAS, the Foundation and USU are committed to the policy that ideas or creative works
produced at the Foundation and USU should be used for the greatest possible public benefit and that
every reasonable incentive should be provided for the prompt introduction of such ideas into public
use, all in a manner consistent with the public interest; and

1

 

     WHEREAS, the Owners, by virtue of assignments from inventors and other parties, are the owners
of or control certain Patent Rights (as hereinafter defined) and have the right to grant licenses
of said Patent Rights, subject only to a royalty-free, nonexclusive license heretofore granted to
or retained by the United States Government; and

     WHEREAS, the Owners have entered into an Amended and Restated Inter-Institutional Sharing
Agreement with an effective date of July 8, 2009, whereby Foundation is responsible for maintenance
of the Patent Rights and for negotiating and administering all licenses of the Patent Rights;

     WHEREAS Licensee has represented to Owners, to induce Owners to enter into this Agreement,
that Licensee is experienced in the development, production, manufacture, marketing, and sale of
products similar to the Licensed Products and the use of processes similar to the Licensed
Processes (both as hereinafter defined) and is willing to undertake as provided in this Agreement a
thorough, vigorous, and diligent program of exploiting the Patent Rights so that public utilization
may result therefrom; and

     WHEREAS Licensee desires to obtain from Owners, and Owners agree to grant to Licensee, a
license upon the terms and conditions set forth herein;

     NOW, THEREFORE, in consideration of the mutual promises and covenants set forth in this
Agreement, the Parties, intending to be legally bound, agree as follows:

ARTICLE I

DEFINITIONS

     As used in this Agreement, the following terms shall have the following meanings:

     1.1 “Affiliate” means, with respect to any Person, any other Person that directly or
indirectly through one or more intermediaries controls, is controlled by, or is under common
control with such Person. For purposes of this definition, the term “controls” (including its
correlative meanings “controlled by” and “under common control with”) means the possession,
directly or indirectly, of the power to direct or cause the direction of the management and
policies of a Person, whether through the ownership of voting securities, by contract, or
otherwise.

     1.2 “Agreement” means this Agreement, including all Appendices hereto, as the same may be
amended from time to time in accordance with the terms hereof.

     1.3 “Business Day” means any day other than a Saturday, a Sunday, or a day on which banking
institutions in Montgomery County, Maryland are closed.

     1.4 “Confidential Information” means information, disclosed by one Party to another Party,
that is treated as proprietary or confidential by the disclosing Party and, at the time of
disclosure, that is marked “proprietary” or “confidential” or that bears a marking or legend of
like import restricting its use, copying, or dissemination or that is identified as being

2

 

confidential in a letter or other written communication sent to the receiving Party prior to
or contemporaneously with disclosure to the receiving Party. Any such information that is in
another form when disclosed, such as oral or visual, shall be treated as Confidential Information
only if and to the extent the disclosing Party informs the receiving Party of the proprietary or
confidential nature of the information prior to or at the time of the disclosure, and thereafter
creates a written record of the disclosure (marked in accordance with this Agreement) and delivers
the written record to the receiving Party promptly, but in no event more than thirty (30) days
after the original disclosure to the receiving Party. Confidential Information does not include
any information that (i) was known to the receiving Party without a duty of confidentiality before
receipt from the disclosing Party as evidenced by written records made prior to such receipt or
disclosure (when such prior knowledge did not become known to such receiving Party through
disclosure by a third party known to the receiving Party to be subject to an obligation to maintain
the confidentiality thereof); (ii) is or becomes a matter of public knowledge through no fault of
the receiving Party or any of its agents; (iii) is rightfully received by the receiving Party from
a third party without a duty of confidentiality; or (iv) is independently developed by the
receiving Party as evidenced by written records of the receiving Party.

     1.5 “Field” means the field of human therapeutics.

     1.6 “Follow-on Intellectual Property” means any intellectual property developed by one or more
of the inventors listed on Appendix A and acquired by the Foundation after the Effective Date that
may be necessary or useful in connection with the development or manufacture of Licensed Products,
to the extent the Foundation has the right to license such intellectual property to Licensee. All
such Follow-on Intellectual Property, if any, shall be expressly included in this Agreement in an
Appendix B to be added pursuant to future modification or amendment signed by the Foundation and
Licensee that satisfies the requirements of Section 10.16. For the avoidance of doubt, Follow-on
Intellectual Property does not include intellectual property of Board or UTMDACC.

     1.7 The term “License” has the meaning set forth in Section 2.1.

     1.8 “Licensed Process” means any process that: (a) is covered in whole or in part by an
unexpired issued or pending claim contained in the Patent Rights, or (b) utilizes any Follow-on
Intellectual Property Rights or Technology Rights.

     1.9 “Licensed Product” means any product or part thereof that: (a) is covered in whole or in
part by an unexpired issued or pending claim contained in the Patent Rights, or (b) is manufactured
by using or is employed to practice a Licensed Process Follow-on Intellectual Property Rights, or
Technology Rights.

     1.10 “Marketing Approval” means the approval or authorization required for the marketing of a
Licensed Product or Licensed Process in the United States, the European Union, or other country
within the Territory, such as the issuance of an approval action by the United States Food and Drug
Administration (“FDA”) on an NDA in the United States, or the issuance of its equivalent by the
European Medicines Agency in the European Union.

3

 

     1.11 “NDA” means a New Drug Application or Biologics License Application filed with the FDA
for Marketing Approval of a Licensed Product or Licensed Process, or an equivalent application
filed with any equivalent agency or governmental authority outside the United States.

     1.12 “Net Sales” means the gross revenues received by Licensee or any sublicensee(s) or
Affiliate(s) from sales, leases, or other transfers of Licensed Products or Licensed Processes,
less the sum of the following: sales discounts actually granted and taken; sales or use taxes
actually paid; import or export duties actually paid; outbound transportation expenses actually
prepaid or actually allowed; and amounts actually allowed or credited due to returns (not exceeding
the original billing or invoice amount), all as recorded by Licensee in Licensee’s official books
and records in accordance with generally accepted accounting practices and consistent with
Licensee’s financial statements and regulatory filings with the United States Securities and
Exchange Commission, if any. No deductions shall be made for commissions paid to individuals,
whether they be with independent sales agencies or regularly employed by and on the payroll of
Licensee or sublicensees, or for the cost of collections.

     1.13 “Non-commercial Research Purposes” means use of Patent Rights for academic research or
other not-for-profit scholarly purposes that are undertaken at a non-profit or governmental
institution that does not use the Patent Rights in the production or manufacture of products for
sale or the performance of services for a fee.

     1.14 “Non-royalty Sublicense Income” means all sublicense issue fees, sublicense maintenance
fees, sublicense milestone payments, and similar non-royalty payments made by sublicensees to
Licensee on account of sublicenses pursuant to this Agreement.

     1.15 “Patent Rights” means any or all of the following intellectual property to the extent
owned or controlled by one or more of the Owners:

          (a) the United States and foreign patents and patent applications listed in Appendix A
(including any and all patents and patent applications, if any, that may be added by a future
modification or amendment of this Agreement that satisfies the requirements of Section 10.16), and
all divisions and continuations of such applications;

          (b) United States and foreign patents issued from the applications listed in Appendix A or
from divisionals or continuations of such applications;

          (c) claims of United States and foreign continuation-in-part applications, and all divisions
and continuations of such continuation-in-part applications, and of the resulting patents, to the
extent that the claims are directed to subject matter specifically described in the United States
or foreign patent applications listed in Appendix A;

          (d) claims of all foreign and United States counterpart patent applications to (a), (b), or
(c) above, and of the resulting patents, to the extent that the claims are directed to subject
matter specifically described in the patents or patent applications described in (a), (b), or (c)
above; and

4

 

          (e) any reissues, renewals, extensions, or supplementary protection certificates of patents
described in (a), (b), (c), or (d) above.

Patent Rights shall not include (c), (d), or (e) above to the extent that the claims are directed
to new matter that is not the subject matter described in (a) above.

     1.16 “Person” means any individual, corporation, limited liability company, general or limited
partnership, joint venture, association, joint stock company, trust, unincorporated business or
organization, government or agency or political subdivision thereof, or other entity, whether
acting in an individual, fiduciary, or other capacity.

     1.17 “Phase I Clinical Trial” means the first human clinical trial on a few individuals to
determine the safety of the drug, dosage, or toxicity limits.

     1.18 “Phase II Clinical Trial” means a controlled clinical study conducted to evaluate the
effectiveness of the drug for a particular indication or indications in patients with the disease
or condition under study and to determine the common short-term side effects and risks.

     1.19 “Phase III Clinical Trial” means: (a) that portion of the drug development and review
process in which an expanded clinical trial is conducted to gather the additional information about
effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of an
investigational new drug, as more specifically defined by the rules and regulations of the FDA,
including 21 C.F.R. § 312.21 or any future revisions or substitutes therefore; or (b) a similar
clinical trial in the European Union or any nation other than the United States. Commencement of a
Phase III Clinical Trial shall be deemed to occur upon the administration of Licensed Product (or
Licensed Process) or placebo to the first patient enrolled in the Phase III Clinical Trial.

     1.20 “Technology Rights” means any of the Owners’ rights in any technical information,
know-how, trade secret, process, procedure, composition, device, method, formula, protocol,
technique, software, design, drawing, or data that are: (a) created before the Effective Date by
one or more of the inventor(s) listed in Appendix A at the respective institution of such inventor
(specifically, with respect to Constantine G. Ioannides, created before the Effective Date by him
at UTMDACC while he was an employee of UTMDACC), and (b) not specifically claimed in Patent Rights
but that are necessary for practicing Patent Rights.

     1.21 “Territory” means worldwide.

     1.22 “Valid Claim” means a claim of: (a) any issued, unexpired Patent Right that has not been
revoked or held unenforceable or invalid by a decision of a court or governmental agency of
competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not
taken within the time allowed for appeal; or (b) any pending application for Patent Right that has
not been cancelled, withdrawn, or abandoned.

5

 

ARTICLE II

GRANT OF RIGHTS

     2.1 The Owners hereby grant to Licensee and Licensee accepts, subject to the terms and
conditions hereof, in the Territory and for the Field: (a) a non-exclusive license to practice
under the Technology Rights and Follow-on Intellectual Property Rights, if any, and (b) an
exclusive (even as to Owners, except as provided in Section 2.4) license to practice under the
Patent Rights (including, to the extent not prohibited by other patents, the right under Patent
Rights in the Field in the Territory to make, have made, use, have used, sell, have sold, export
and import Licensed Products and to practice Licensed Processes) (collectively, the “License”),
until the expiration of this Agreement, unless this Agreement shall be sooner terminated in
accordance with the terms hereof.

     2.2 In order to establish a period of commercial exclusivity for Licensee, the Owners agree
that they will not grant, in the Territory for the Field, any other license to practice under the
Patent Rights, except as required by the obligations related to Section 2.4(a) or as permitted in
Section 2.4(b) or Section 2.4(d), during the period of time commencing with the Effective Date and
ending with the first to occur of:

          (a) the expiration of all Patent Rights;

          (b) a court or tribunal, in a final decision not subject to further appeal, declaring invalid
or unenforceable all claims in the Patent Rights;

          (c) the abandonment of all claims in the Patent Rights; or

          (d) the termination of this Agreement or the termination of the exclusivity of the License in
accordance with Article IX.

     2.3 Subject to the Foundation’s prior approval, which approval shall not be unreasonably
withheld or delayed, Licensee shall have the right to grant sublicenses hereunder via written
sublicense agreements. The License granted to Licensee hereunder does not extend to any Affiliate
of Licensee unless and until such Affiliate enters into a written sublicense agreement with
Licensee that is consistent with the requirements hereof and the Foundation approves the written
sublicense agreement.

          (a) In all sublicenses granted hereunder, Licensee shall provide that the sublicense is
subject and subordinate to all terms and conditions of this Agreement, except: (i) the sublicensee
may not grant any sublicenses except with the Foundation’s prior express written approval, and (ii)
any royalty or other payment paid by the sublicensee to Licensee may exceed the rate set forth in
this Agreement. Licensee shall attach a copy of this Agreement to any sublicense agreement and
shall provide a complete copy of the sublicense agreement to the Foundation promptly after signing
by the parties thereto.

6

 

          (b) Licensee may not receive from any sublicensee anything of value in lieu of cash payments
in consideration for any sublicense under this Agreement, without the Foundation’s prior express
written approval.

          (c) Sublicenses may extend past the expiration date of the exclusive period but any
exclusivity of such sublicenses shall expire upon the termination or expiration of Licensee’s
exclusivity. Upon any termination of this Agreement, sublicensees’ rights shall also terminate,
subject to Section 9.3.

     2.4 The granting and exercise of the License is subject to the following conditions:

          (a) The U.S. Government retains a nonexclusive, nontransferable, irrevocable, world-wide,
paid-up license to practice all invention(s) covered by the Patent Rights, Follow-on Intellectual
Property Rights, or Technology Rights and to have such invention(s) practiced by or on behalf of
the U.S. Government and on behalf of any foreign government or international organization pursuant
to any existing or future treaty or agreement to which the U.S. Government is a signatory. This
Agreement is explicitly made subject to the Government’s rights under any such license and any
applicable law or regulation. To the extent that there is a conflict between any such license of
the U.S. Government, applicable law or regulation and this Agreement, the terms of such Government
license, applicable law or regulation shall prevail.

          (b) The Foundation, the USU, Board and UTMDACC reserve the rights to make and use, and grant
to others non-exclusive licenses to make and use, for Non-commercial Research Purposes, the subject
matter described or claimed in Patent Rights. The Foundation, the USU, Board and UTMDACC reserve
the rights to make and use, and grant to others non-exclusive licenses to make and use, for any and
all purposes, the subject matter described or claimed in Technology Rights. The Foundation and the
USU reserve the rights to make and use, and grant to others non-exclusive licenses to make and use,
for any and all purposes, the subject matter described or claimed in Follow-on Intellectual
Property Rights.

          (c) Licensee shall cause any Licensed Product produced for use or sale in the United States to
be manufactured substantially in the United States or its territories.

          (d) Notwithstanding anything to the contrary in this Agreement, any license or other rights
granted to Licensee herein are subject to the following rights retained by Board and UTMDACC: (i)
Board and UTMDACC retain the right to publish the general scientific findings from research related
to inventions, discoveries, know-how, and information covered by Patent Rights or Technology Rights
or described in UTMDACC Invention Disclosure Report MDA00-043 entitled “Induction of Tumor Immunity
by Variants of FBP”; and (ii) Board and UTMDACC retain the right to use the inventions,
discoveries, know-how, and information covered by Patent Rights or Technology Rights or described
in UTMDACC Invention Disclosure Report MDA00-043 entitled “Induction of Tumor Immunity by Variants
of FBP”, for patient care, research, teaching, and other educationally-related purposes.

     2.5 The License granted hereunder shall not be construed to confer any rights upon Licensee
(or sublicensees, if any) by implication, estoppel, or otherwise as to any technology

7

 

not included in the Patent Rights, the Follow-on Intellectual Property Rights, or the
Technology Rights as defined herein.

ARTICLE III

LICENSE FEES AND MILESTONE AND ROYALTY PAYMENTS

     3.1 Licensee shall pay to the Foundation a non-creditable, non-refundable License issue
royalty in the sum of [***] within thirty (30) days after the Effective Date. Additionally,
Licensee shall pay the Foundation a non-creditable, nonrefundable License issue royalty in the sum
of [***] for each additional item of Follow-on Intellectual Property, such payment to be paid
within thirty (30) days after the effective date of the associated modification or amendment adding
such Follow-on Intellectual Property to Appendix B

     3.2 Licensee shall, commencing December 31, 2011, pay to the Foundation semi-annually, within
sixty (60) days after each calendar half year ending June 30 and December 31, on a
country-by-country basis, a royalty of [***] of Net Sales in any and all jurisdictions in which a
Licensed Product or Licensed Process is covered by at least one Valid Claim, and [***] of Net
Sales in all other jurisdictions. In the case of sublicenses, Licensee shall also pay to the
Foundation a royalty of [***] of Non-royalty Sublicense Income.

     3.3 Licensee shall pay the Foundation annually, no later than the anniversary of the Effective
Date indicated below, the following minimum, annual, non-refundable License maintenance royalties:

          (a) First anniversary of the Effective Date, the sum of [***];

          (b) Second anniversary of the Effective Date, the sum of [***];

          (c) Third anniversary of the Effective Date, the sum of [***]; and

          (d) Fourth anniversary of the Effective Date and every anniversary of the Effective Date
thereafter, the sum of [***], which commencing with the year after the first sale of Licensed
Product or Licensed Process, shall be creditable against other royalties, if any, due under Section
3.2 for the same calendar year only, but shall not be credited against any milestone payments, if
any, due pursuant to Section 3.4 nor against royalties due for any other calendar year.

     3.4 Licensee shall pay to the Foundation the following milestone payments:

          (a) [***] for each additional item of Follow-on Intellectual Property within thirty (30) days
of issuance of the first patent in the Territory related to any portion of such Follow-on
Intellectual Property;

          (b) [***] within thirty (30) days of the start of the first Phase I Clinical Trial;

          (c) [***] within thirty (30) days of the start of the first Phase II Clinical Trial;

8

 

          (d) [***] within thirty (30) days of the start of the first Phase III Clinical Trial;

          (e) [***] within thirty (30) days following the filing of the first NDA (or equivalent filing)
for any Licensed Product;

          (f) [***] within thirty (30) days following the first Marketing Approval of any Licensed
Product; and

          (g) [***] within thirty (30) days following the date that cumulative total Net Sales in the
Territory reach [***].

     3.5 All payments due hereunder shall be paid in full, without deduction for any taxes or other
fees imposed by any government or any transfer, collection, or similar charges; any such tax, fee,
or charge shall be paid by Licensee.

     3.6 Royalty payments shall be paid, by check or by wire transfer, in United States dollars in
Rockville, Maryland, or at such other place and manner as the Foundation may designate in writing
consistent with the laws and regulations controlling in any foreign country. If any currency
conversion is required in connection with any payments due hereunder, such conversion shall be made
by using the exchange rate existing in the United States as reported in The Wall Street Journal on
the last Business Day of the calendar half-year reporting period to which such payments relate.

     3.7 [***] shall be due to the Foundation for any Licensed Product as to which the manufacture,
use, lease, or sale is, or shall be, covered by more than one Patent Right licensed hereunder.

     3.8 If Licensee is required to pay royalties to a third party to avoid infringing such third
party’s intellectual property rights, as documented by a written advice of Licensee’s patent
counsel, Licensee shall be entitled to reduce the royalty payments made pursuant to Section 3.2 by
the amounts paid to such thirty party; provided, however, that the amounts paid pursuant to Section
3.2 will not be reduced by more than [***] and in no event shall be less than [***]. Such
reduction of royalty payments paid pursuant to Section 3.2 shall occur only in the same calendar
year as such required payment is made to such third party. Any such required payment shall not be
applied to reduce any milestone payments, nor to reduce any royalties due for any other calendar
year.

ARTICLE IV

DUE DILIGENCE

     4.1 Licensee shall use its commercially reasonable efforts to bring one or more of the
Licensed Products or the Licensed Processes to market, in the Territory for the Field, through a
thorough, vigorous, and diligent program for exploitation of the Patent Rights and to continue
active, diligent development and marketing efforts for such Licensed Products and Licensed

9

 

Processes throughout the life of this Agreement. Thereafter, until the expiration of this
Agreement, Licensee shall endeavor to keep the Licensed Products and the Licensed Processes
continuously available to the public in the Territory for the Field.

     4.2 In addition, Licensee shall adhere to the following milestones:

          (a) Licensee shall deliver to the Foundation on or before sixty (60) days following the
Effective Date a business plan showing the estimated amount of money, number and kind of personnel,
and time budgeted and planned for each phase of development of the Licensed Products and the
Licensed Processes during the period ending on the first anniversary of the Effective Date.
Licensee shall provide an updated, similarly detailed business plan to the Foundation each year on
or before the anniversary of the Effective Date.

          (b) Licensee shall enter into a Phase I Clinical Trial no later than six (6) months after the
Effective Date.

          (c) Licensee shall enter into a Phase II Clinical Trial no later than three (3) years after
the Effective Date.

          (d) Licensee shall enter into a Phase III Clinical Trial no later than seven (7) years after
the Effective Date.

          (e) Licensee shall have commenced the first sale of any Licensed Product no later than twelve
(12) years after the Effective Date.

ARTICLE V

REPORTING

     5.1 No later than sixty (60) days after December 31 of each calendar year, Licensee shall
provide to the Foundation a written annual Progress Report describing progress on research and
development, regulatory approvals, manufacturing, sublicensing, marketing, and sales during the
most recent twelve (12) month period ended December 31 and plans for the forthcoming year. The
Progress Report shall describe the status of Licensee’s efforts to develop and commercialize
Licensed Product(s) or Licensed Process(es) in sufficient detail to enable the Foundation to
reasonably determine whether anticipated performance and payment milestones have been met and to
provide assurance that Licensee is developing Licensed Product(s) or Licensed Process(es). If
multiple technologies are covered by the License hereunder, the Progress Report shall provide the
information set forth above for each technology. If progress differs in any material respect from
that anticipated in the plan required under Section 4.2(a), Licensee shall explain the reasons for
the difference and propose a modified development plan for the Foundation’s review and approval,
not to be unreasonably withheld. Licensee shall also provide any reasonable additional data the
Foundation requires to evaluate Licensee’s performance.

10

 

     5.2 Licensee shall report to the Foundation the date of the first sale of Licensed Products
(or use or sale of Licensed Processes) in each country within thirty (30) days of occurrence.

     5.3 Royalty Reports.

          (a) Licensee shall, commencing December 31, 2011, submit to the Foundation, within sixty (60)
days after each calendar half year ending June 30 and December 31 during the term of this
Agreement, a Royalty Report setting forth for such half year at least the following information:

          (i) the number of Licensed Products sold by Licensee and all sublicensees in each
country;

          (ii) total dollar amount of billings, invoices, and receipts for Licensed Products sold
by Licensee and all sublicensees in each country (together with an accounting for currency
conversions, if any);

          (iii) an accounting for all Licensed Processes used or sold by Licensee and all
sublicensees in each country;

          (iv) the calculation of Net Sales, including applicable deductions;

          (v) the amount of Non-royalty Sublicense Income received by Licensee;

          (vi) an accounting for any deduction made pursuant to Section 3.8; and

          (vii) the amount of royalty due to the Foundation for the reporting period or, if no
royalties are due for any reporting period, the statement that no royalties are due.

Such Royalty Report shall be certified as correct by an officer of Licensee and shall include a
detailed listing of all deductions from royalties otherwise due pursuant to this Agreement.

          (b) Contemporaneous with the submission of each Royalty Report, Licensee shall pay to the
Foundation the amount of royalty due with respect to such half year. If multiple technologies are
covered by the License granted hereunder, Licensee shall specify which Patent Rights are utilized
for each Licensed Product and Licensed Process included in the Royalty Report.

          (c) Late payments shall be subject to a charge of one and one-half percent (1-1/2%) per month,
or $250, whichever is greater.

     5.4 In the event of an acquisition, merger, change of corporate name, or change of
organization or identity, Licensee shall notify the Foundation in writing within thirty (30) days
of such event.

11

 

     5.5 If Licensee or any Affiliate or sublicensee (or optionee) does not qualify or ceases to
qualify as a “small entity” as provided by the United States Patent and Trademark Office, Licensee
shall notify the Foundation immediately.

ARTICLE VI

RECORD KEEPING

     6.1 Licensee shall keep, and shall require its sublicensees to keep, accurate records
(together with supporting documentation) of Licensed Products and Licensed Processes made, used or
sold under this Agreement, appropriate to determine the amount of royalties due to the Foundation
hereunder. Such records shall be retained for at least three (3) years following the end of the
reporting period to which they relate. They shall be available during normal business hours, on not
less than ten (10) days’ prior notice from the Foundation, for examination by an accountant
selected by the Foundation, for the sole purpose of verifying reports and payments hereunder,
provided that the Foundation shall have the right to conduct such an examination not more than once
in any calendar year and only with respect to prior years that have not previously been subject to
such examination. In conducting examinations pursuant to this section, the Foundation’s accountant
shall have access to all records that the Foundation reasonably believes to be relevant to the
calculation of royalties and other payments required under Article III.

     6.2 The Foundation’s accountant shall not disclose to the Foundation any information other
than information relating to the accuracy of reports and payments made hereunder. In cases of
inaccurate reports and payment, Licensee shall promptly pay the Foundation any additional sum that
would have been payable to the Foundation had the Licensee reported correctly, plus interest on
said sum at the rate of one and one half percent (1-1/2%) per month.

     6.3 Such examination by the Foundation’s accountant shall be at the Foundation’s expense,
except that if such examination shows an underreporting or underpayment in excess of the greater of
(i) five percent (5%) or (ii) Ten Thousand Dollars ($10,000) for any twelve (12) month period, then
Licensee shall pay the Foundation the reasonable cost of such examination (as well as any
additional sum that would have been payable to the Foundation had the Licensee reported correctly,
plus interest on said sum at the rate of one and one half percent (1-1/2%) per month).

ARTICLE VII

DOMESTIC AND FOREIGN PATENT FILING AND MAINTENANCE

     7.1 Licensee Prosecution

          (a) Owners grant Licensee the right to be responsible for the preparation, filing, prosecution
and maintenance of any and all Patent Rights in the Field in the Territory (as such terms are
defined herein). Licensee agrees to prosecute and maintain at Licensee’s expense the patent
applications listed under Appendix A. Licensee further agrees to file at Licensee’s expense any
additional continuation or divisional application(s) required to retain all embodiments of Patent
Rights contained in said patent applications. Licensee agrees not to

12

 

abandon or otherwise undermine prosecution of any Patent Rights without the prior written
approval of the Foundation. If UTMDACC or Foundation has reasonable concerns regarding the quality
of the legal representation provided by Licensee in connection with the prosecution of the Patent
Rights, then (i) Foundation or UTMDACC shall give Licensee written notice to terminate its
prosecution of Patent Rights, (ii) UTMDACC and Foundation will appoint new legal counsel to
prosecute Patent Rights that is reasonably acceptable to Licensee, and (iii) Licensee will pay for
the cost of filing, preparation, prosecution, and maintenance of Patent Rights.

          (b) Licensee shall consult with the Foundation as to the preparation, filing, prosecution and
maintenance of the Patent Rights, and agrees to keep the Foundation promptly and fully informed of
the course of patent prosecution of the Patent Rights by providing the Foundation with copies of
all documents relevant to any such preparation, filing, prosecution, or maintenance, including but
not limited to substantive communications and notices, search reports, third party observations
submitted to or received from patent offices throughout the Territory, foreign patent applications,
Office Actions and Examination Reports from patent offices, and proposed draft responses. The
Foundation shall have the right to review all such documents, prior to their submission, and may
offer recommendations to Licensee to amend such contemplated preparation, filing, prosecution, or
maintenance, and provide a list of the countries where the Foundation desires Licensee to file
patent applications. Licensee will make a reasonable effort to implement such Foundation
recommendations, provided the Foundation recommendations are acceptable to outside patent counsel
and are received in sufficient time to meet any pertinent deadlines. The Foundation shall provide
such patent consultation to Licensee at no cost to Licensee.

          (c) In the event the Licensee elects not to, or fails to, continue prosecution, in whole or in
part, of any Patent Rights in any particular country or countries, the Foundation shall have the
right (but not the obligation) at its own expense to undertake the prosecution and maintenance of
the Patent Rights. The Licensee shall notify the Foundation in writing of any election not to
pursue the prosecution or maintenance of any Patent Rights at least sixty (60) days prior to any
applicable deadline or loss of rights. Licensee shall have an obligation to pay a royalty on Net
Sales of Licensed Products or Licensed Processes in any country in which Licensee discontinued
prosecuting or abandoned Patent Rights. In addition, Licensee shall reimburse Foundation for all
patent prosecution expenses that Foundation reasonably incurs pursuant to its election to prosecute
Patent Rights under this Section 7.1(c) in any country in which Licensee has Net Sales.

          (d) Foundation shall provide reasonable efforts to aid Licensee in obtaining signatures or
inventor assistance as necessary to further prosecution and to secure the full protection and
ownership of all rights in and to the Licensed Products and the Licensed Processes, but Licensee
acknowledges that inventors include employees of the U.S. Government and other individuals, none of
whom are employed by the Foundation. Licensee further acknowledges that, as of the Effective Date,
none of the inventors listed on Appendix A are employees of System, Board, or UTMDACC.

     7.2 After execution of this Agreement and within thirty (30) days of the Foundation’s
submission of an invoice, Licensee shall reimburse the Foundation for up to [***] of all third

13

 

party expenses the Owners have incurred and paid prior to the Effective Date for the
preparation, filing, prosecution, and maintenance of Patent Rights. If expenses are incurred by
Foundation after the Effective Date that are reimbursable by Licensee under the terms hereof, the
Licensee shall reimburse the Foundation for all such future third party expenses within thirty (30)
days after Licensee’s receipt of invoices from the Foundation. Payment of these invoices that is
made more than the number of days specified above after submission shall be considered late and
subject to interest charges of one and one-half percent (1-1/2%) per month.

     7.3 The Foundation and Licensee shall cooperate fully in the preparation, filing, prosecution
and maintenance of Patent Rights licensed to Licensee hereunder, executing all papers and
instruments or requiring employees or agents to execute such papers and instruments so as to enable
the Foundation or Licensee to apply for, to prosecute, and to maintain patent applications and
patents in the Foundation’s name in any country. Each Party shall provide to the other prompt
notice as to all matters that come to its attention and that may affect the preparation, filing,
prosecution, or maintenance of any such patent applications or patents; provided however, that with
respect to Board and UTMDACC, such obligation shall be limited to matters that come to the
attention of UTMDACC’s Office of Technology Commercialization.

     7.4 Licensee may elect to surrender its Patent Rights in any country upon sixty (60) days
written notice to the Foundation. Such notice shall not relieve Licensee from responsibility for
Patent Right-related expenses incurred prior to the expiration of the sixty (60)-day notice period
(or such longer period specified in Licensee’s notice).

     7.5 The Parties agree that they share a common legal interest to get valid enforceable patents
and will keep all privileged information received pursuant to this Article confidential.

ARTICLE VIII

INFRINGEMENT

     8.1 With respect to any Patent Rights that are exclusively licensed to Licensee pursuant to
this Agreement, Licensee shall have the right, within the Territory, to prosecute in its own name
and at its own expense any infringement of such patent, so long as such License is exclusive at the
time of the commencement of such action. The Foundation agrees to notify Licensee promptly of each
infringement of such patents of which the Foundation is or becomes aware. Before Licensee
commences an action with respect to any infringement of such patents, Licensee shall give careful
consideration to the views of the Foundation and to potential effects on the public interest in
making its decision whether or not to sue.

          (a) If Licensee elects to commence an action as described above, Foundation may, to the extent
permitted by law and at the Foundation’s own expense, elect to join as a party in that action.
Regardless of whether the Foundation elects to join as a party, the Foundation shall cooperate
fully with Licensee in connection with any such action.

          (b) If the Foundation elects to join as a party pursuant to subsection (a), the Foundation
shall jointly control the action with Licensee.

14

 

     8.2 If Licensee elects to commence an action as described above, Licensee may deduct from its
royalty payments to the Foundation with respect to the patent(s) subject to suit an amount not
exceeding [***] of Licensee’s expenses and costs of such action, including reasonable attorneys’
fees; provided, however, that such reduction shall not exceed [***] of the total royalty due to the
Foundation with respect to the patent(s) subject to suit for each calendar year. If such [***] of
Licensee’s expenses and costs exceeds the amount of royalties deducted by Licensee for any calendar
year, Licensee may to that extent reduce the royalties due to the Foundation from Licensee in
succeeding calendar years, but never by more than [***] of the total royalty due in any one year
with respect to the patent(s) subject to suit.

     8.3 No settlement, consent, judgment or other voluntary final disposition of the suit may be
entered into without the prior written consent of the Foundation and UTMDACC, which consent shall
not be unreasonably withheld or delayed.

     8.4 Recoveries or reimbursements from actions commenced pursuant to this Article shall first
be applied to reimburse Licensee and the Foundation for litigation costs (excluding Licensee
litigation costs deducted from royalty payments pursuant to Section 8.2) not paid from royalties
and then to reimburse the Foundation for royalties deducted by Licensee pursuant to Section 8.2.
Licensee, and Foundation shall share any remaining recoveries or reimbursements [***].

     8.5 If Licensee elects not to exercise its right to prosecute an infringement of the Patent
Rights pursuant to this Article, the Foundation may do so at Foundation’s own expense, controlling
such action and retaining all recoveries therefrom. Licensee shall cooperate fully with the
Foundation in connection with any such action.

     8.6 Without limiting the generality of Section 8.5, the Foundation may, at its election and by
notice to Licensee, establish a time limit of sixty (60) days for Licensee to decide whether to
prosecute any infringement of which the Foundation is or becomes aware. If, by the end of such
sixty (60)-day period, Licensee has not commenced such an action, the Foundation may prosecute such
an infringement at its own expense, controlling such action and retaining all recoveries therefrom.
With respect to any such infringement action prosecuted by the Foundation in good faith, Licensee
shall pay over to Foundation any payments (whether or not designated as “royalties”) made by the
alleged infringer to Licensee under any existing or future sublicense authorizing Licensed Products
or Licensed Processes, up to the amount of the Foundation’s unreimbursed litigation expenses
(including, but not limited to, reasonable attorneys’ fees).

     8.7 If a declaratory judgment action is brought naming Licensee as a defendant and alleging
invalidity of any of the Patent Rights, the Foundation may elect to take over the sole defense of
the action at its own expense. Licensee shall cooperate fully with the Foundation in connection
with any such action.

     8.8 Subject to Section 2.4, during the exclusive period of Licensee’s License hereunder,
Licensee shall have the sole right, in accordance with the terms and conditions hereof, to
sublicense Patent Rights to any alleged infringer within the Territory for the Field.

15

 

Any upfront fees paid in connection with such sublicense shall be shared [***] between
Licensee and the Foundation; other royalties shall be treated in accordance with Article III.

     8.9 Nothing in this Article VIII shall constitute a waiver or surrender of any rights by Board
or UTMDACC to enforce any rights owned or controlled by Board or UTMDACC.

ARTICLE IX

TERMINATION OF AGREEMENT

     9.1 This Agreement, unless terminated as provided herein, shall remain in effect until (a) the
last patent or patent application in Patent Rights has expired or been abandoned or (b) fifteen
(15) years from the Effective Date, whichever is later.

     9.2 The Foundation may terminate this Agreement in the circumstances set forth in this
Section, and any such termination shall be effective immediately upon the Foundation giving written
notice to Licensee of any of the following:

          (a) if Licensee does not make a payment due hereunder and fails to cure such non-payment
(including the payment of interest in accordance with Section 5.3(c)) within thirty (30) days after
the date of notice in writing of such non-payment by the Foundation;

          (b) if Licensee defaults in any of its material obligations under Sections 10.4(c), 10.4(d),
and 10.4(e) to procure and maintain insurance;

          (c) at any time after two (2) years from the Effective Date of this Agreement, the Foundation
may, in its sole discretion, either terminate this Agreement and the License granted hereunder or
render the exclusive portion of the License non-exclusive if, in the Foundation’s reasonable
judgment, the Progress Reports furnished by Licensee do not demonstrate that Licensee has:

          (i) either (A) put the licensed subject matter into commercial use in the Territory,
directly or through a sublicense, and is keeping the licensed subject matter continuously
available to the public, or (B) has been and continues to be engaged in research,
development, manufacturing, marketing or sublicensing activity appropriate to achieving the
purposes set forth in Section 4.1; and

          (ii) met all relevant performance milestone(s) for the period covered by the most
recent Progress Report and all preceding Progress Reports;

          (d) if Licensee: is unable to pay its debts as such debts become due; makes a general
assignment for the benefit of creditors; has a petition in bankruptcy or a suit seeking
reorganization, liquidation, dissolution, or similar relief filed against it and such petition or
suit is not dismissed within sixty (60) days of its filing; or files or permits the filing of any
petition or answer seeking to adjudicate itself bankrupt or insolvent, or seeking for itself any
liquidation, winding up, reorganization, arrangement, adjustment, protection, relief, or
composition of Licensee or its debts under any law relating to bankruptcy, insolvency, or
reorganization or relief

16

 

of debtors, or seeking or consenting to the appointment of a trustee, custodian, receiver,
liquidator or other similar official for Licensee or for any substantial part of its property; or
takes any corporate action to authorize any of the foregoing actions;

          (e) if an examination by Foundation’s accountant pursuant to Article VI shows an
underreporting or underpayment by Licensee in excess of fifteen percent (15%) for any twelve (12)
month period;

          (f) if Licensee is convicted of a felony relating to the manufacture, use, or sale of any
Licensed Product or Licensed Process; or

          (g) except as provided in subsections (a), (b), (c), (d), (e), and (f) above, if Licensee
defaults in the performance of any obligations under this Agreement and the default has not been
remedied within ninety (90) days after the date of notice in writing of such default by the
Foundation.

     9.3 Licensee shall provide, in all sublicenses granted by it under this Agreement, that
Licensee’s interest in such sublicenses shall at the Foundation’s option terminate or be assigned
to the Foundation and Board upon termination of this Agreement.

     9.4 This Agreement may be terminated at any time by mutual written agreement between the
Parties, subject to any terms herein which survive termination. Upon termination, Licensee shall
submit a final Royalty Report to the Foundation and any royalty payments, including royalty
payments on any and all future sales of Licensed Products made but not yet sold at the time of
termination, and unreimbursed patent expenses invoiced under this Agreement by the Foundation prior
to termination shall become immediately payable.

     9.5 Upon termination, Licensee shall promptly provide to Foundation all data, including all
pre-clinical data, clinical data, manufacturing data, and marketing data, derived during
development or attempted development of Licensed Products or Licensed Processes. Licensee shall
also provide to Foundation copies of all FDA submissions and correspondence related to Licensed
Products or Licensed Processes. In addition, Licensee shall promptly provide Foundation the entire
official file wrapper concerning prosecution of Patent Rights whether from outside counsel or
internal counsel.

     9.6 Upon termination, Licensee grants to Foundation and Board a nonexclusive royalty-bearing
license with the right to sublicense with respect to improvements made by Licensee (including
improvements licensed by Licensee from third parties to the extent Licensee has the right to grant
such sublicenses). Licensee and Foundation agree to negotiate in good faith the royalty rate for
such nonexclusive license. Foundation’s and Board’s right to sublicense others hereunder is solely
for the purpose of permitting others to develop and commercialize the entire technology related to
the subject matter of this Agreement.

     9.7 Articles I, VI, and X and Sections 2.5, 5.3 (only as it relates to any overdue Royalty
Report(s) and to the Royalty Report for the half year during which the termination occurs), 7.2,
8.3, 8.4, 9.5, 9.6, and 9.7 shall survive any expiration or termination of this

17

 

Agreement indefinitely. Additionally, any rights or remedies arising out of a breach or
violation of any terms of this Agreement will survive any expiration or termination of this
Agreement. The expiration or termination of this Agreement shall not discharge any Party from any
obligation that it owes to another Party by reason of any loss, cost, damage, expense, liability,
or contractual duty that occurs or arises (or the circumstances, events, or basis of which occurs
or arises) prior to such expiration or termination, and shall not affect the right of any Party to
institute or maintain any action for damages relating to any breach of this Agreement by another
Party prior to the date of termination. It is the intent of the Parties that any such obligation
owed by a Party to another Party arising before the date of expiration or termination (whether the
same shall be known or unknown at such date, or whether the circumstances, events, or basis of the
same shall be known or unknown at such date), including royalty obligations (computed in accordance
with Article III) on sales made or ordered prior to the date of termination or expiration,
indemnification obligations, and confidentiality obligations, shall survive the expiration or
termination of this Agreement.

ARTICLE X

MISCELLANEOUS PROVISIONS

     10.1 Rules of Construction. This Agreement is to be interpreted in accordance with
the following rules of construction:

          (a) Number and Gender. All definitions of terms apply equally to both the singular
and plural forms of the terms defined. Whenever the context may require, any pronoun shall include
the corresponding masculine, feminine, and neuter forms.

          (b) Including; Herein; Etc. The words “include,” “includes,” and “including” are
deemed to be followed by the phrase “without limitation.” The words “herein,” “hereof,” and
“hereunder” and words of similar import refer to this Agreement (including all Appendices) in its
entirety and are not limited to any part hereof, unless the context shall otherwise require. The
word “or” is not exclusive and means “and/or.”

          (c) Sales. The terms “sold,” “sell,” and “sale(s)” include leases and other transfers
and similar transactions for consideration.

          (d) Subdivisions and Attachments. All references in this Agreement to Articles,
Sections, subsections, paragraphs, and Appendices are, respectively, references to Articles,
Sections, subsections, and paragraphs of, and Appendices to, this Agreement, unless otherwise
specified.

          (e) References to Documents and Laws. All references to this Agreement or any
Appendix hereof are to it as amended, modified, and supplemented from time to time in accordance
with the terms of this Agreement. All references to (i) any other agreement or instrument or (ii)
any statute, law, regulation, permit, or similar item are to it as amended and supplemented from
time to time (and, in the case of a statute, law or regulation, to any corresponding provisions of
successor statutes, laws, or regulations), unless otherwise specified.

18

 

          (f) References to Days. Any reference in this Agreement to a “day” or number of
“days” (without the explicit qualification “Business”) is a reference to a calendar day or number
of calendar days. If any action or notice is to be taken or given on or by a particular calendar
day, and such calendar day is not a Business Day, then such action or notice may be taken or given
on the next Business Day.

          (g) Examples. If, in any provision of this Agreement any example is given (through
the use of the words “such as,” “for example,” “e.g.,” or otherwise) of the meaning, intent, or
operation of any provision of this Agreement, such example is intended to be illustrative only and
not exclusive.

          (h) Currency. Except as expressly provided herein, all prices or other monetary
amounts stated in this Agreement are, and all monetary amounts stated in any report to be delivered
pursuant hereto shall be, stated in United States Dollars.

          (i) Participation in Drafting. All Parties and their respective legal counsel have
participated, or had the opportunity to participate, in the drafting of this Agreement, and this
Agreement will be construed simply and according to its fair meaning and not strictly for or
against any Party.

     10.2 Representations and Warranties.

          (a) Foundation and Licensee each covenants, represents, and warrants that: it is a corporation
duly organized and validly existing under the laws of the jurisdiction in which it is incorporated;
this Agreement is legally binding upon it and enforceable in accordance with its terms; and the
execution, delivery and performance of this Agreement does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a party or by which it may be bound,
nor violate any material law or regulation of any governmental or regulatory authority having
jurisdiction over it. Foundation further covenants, represents, and warrants to Licensee that:

          (i) Owners are the sole owners of the Patent Rights and have the right to grant the
License to Licensee as set forth in this Agreement;

          (ii) Foundation has not granted any rights in the Licensed Patents or the Licensed
Process that are inconsistent with or that limit the rights granted to Licensee under this
Agreement; and

          (iii) Foundation is not aware that any of the Licensed Patents or the Licensed Process
infringes the rights of any third party.

          (b) Except for the rights, if any, of the Government of the United States of America as set
forth herein (and the rights of Foundation), Board represents and warrants its belief that (i) it
is an owner or co-owner of the right, title, and interest in and to Patent Rights and Technology
Rights, (ii) it has the right to grant licenses thereunder, and (iii) it has not knowingly

19

 

granted licenses thereunder to any other entity that would restrict rights granted hereunder
except as stated herein.

          (c) The Owners do not warrant the validity of the Patent Rights licensed hereunder and make no
representations whatsoever with regard to the scope of the licensed Patent Rights or that such
Patent Rights may be exploited by Licensee or any sublicensee without infringing other patents.

          (d) EXCEPT AS EXPRESSLY PROVIDED IN SECTION 10.2(a), FOUNDATION EXPRESSLY DISCLAIMS ANY AND
ALL IMPLIED AND EXPRESS WARRANTIES AND MAKE NO WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE OF THE PATENT RIGHTS, OR INFORMATION SUPPLIED BY THE FOUNDATION, OR OF THE
LICENSED PROCESSES OR LICENSED PRODUCTS CONTEMPLATED BY THIS AGREEMENT.

          (e) LICENSEE UNDERSTANDS AND AGREES THAT NEITHER BOARD NOR UTMDACC, BY THIS AGREEMENT, MAKES
ANY REPRESENTATION AS TO THE OPERABILITY OR FITNESS FOR ANY USE, SAFETY, EFFICACY, APPROVABILITY BY
REGULATORY AUTHORITIES, TIME AND COST OF DEVELOPMENT, PATENTABILITY, OR BREADTH OF THE SUBJECT
MATTER OF THIS AGREEMENT OR AS TO WHETHER ANY PATENT COVERED BY THE LICENSED PATENTS IS VALID OR AS
TO WHETHER THERE ARE ANY PATENTS NOW HELD, OR WHICH WILL BE HELD, BY OTHERS OR BY HJF, BOARD OR
UTMDACC, NOR DOES BOARD OR UTMDACC MAKE ANY REPRESENTATION THAT THE INVENTIONS CONTAINED IN THE
LICENSED PATENTS DO NOT INFRINGE ANY OTHER PATENTS NOW HELD OR THAT WILL BE HELD BY OTHERS OR BY
HJF OR BOARD.

     10.3 Limitation of Liability. IN NO EVENT SHALL ANY PARTY (OR SYSTEM) BE LIABLE FOR
ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION
DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES, OR FOR INJURY TO PERSONS
OR PROPERTY) ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS
OF WHETHER SUCH PARTY KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. THE OWNERS’
AGGREGATE LIABILITY FOR ALL DAMAGES OF ANY KIND RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER
SHALL NOT EXCEED THE AMOUNT PAID BY LICENSEE TO THE FOUNDATION UNDER THIS AGREEMENT. THE FOREGOING
EXCLUSIONS AND LIMITATIONS SHALL APPLY TO ALL CLAIMS AND ACTIONS OF ANY KIND, WHETHER BASED ON
CONTRACT, TORT (INCLUDING BUT NOT LIMITED TO NEGLIGENCE), OR ANY OTHER GROUNDS. NOTWITHSTANDING
THE FOREGOING, NOTHING IN THIS SECTION 10.3 SHALL LIMIT LICENSEE’S INDEMNIFICATION OBLIGATIONS
UNDER THIS AGREEMENT OR LIMIT THE SCOPE OF LIABILITY FOR ANY CLAIMS AGAINST LICENSEE FOR
INDEMNIFICATION OR MISAPPROPRIATION OR INFRINGEMENT OF ANY OWNER’S INTELLECTUAL PROPERTY RIGHTS.

20

 

     10.4 Indemnification and Insurance.

          (a) Licensee shall indemnify, defend and hold harmless each and every Owner, System (and its
member institutions, including UTMDACC), Board, and their current and former Regents, directors,
board members, trustees, officers, employees, students, scientists, Affiliates, and agents and
their respective successors, heirs and assigns (collectively, the “Indemnitees”), from and against
any and all claims, demands, causes of action, liabilities, costs, expenses, damages, deficiencies,
losses or obligations of any kind or nature (including reasonable attorneys’ fees and other costs
and expenses of litigation) (collectively “Claims”) based upon, arising out of, or otherwise
relating to this Agreement, including without limitation (i) any of the foregoing caused by, or
arising out of, or resulting from, the exercise or practice by Licensee, its officers, its
affiliates or their officers, employees, agents, sublicensees (if any), or representatives of the
rights granted hereunder, (ii) any Claims arising on account of any injury or death of persons or
damage to property, or (iii) any causes of action relating to product liability concerning any
product, process, or service made, used, or sold pursuant to any right or license granted under
this Agreement. Licensee’s obligation to defend Board, System, and UTMDACC as set forth in this
Section 10.4(a) or under any other provision of this Agreement shall apply to the extent authorized
by the Texas Constitution and the laws of the State of Texas and shall be subject to the statutory
duties of the Texas Attorney General.

          (b) To the extent authorized by the Texas Constitution and the laws of the State of Texas and
subject to the statutory duties of the Texas Attorney General, Licensee shall, at its own expense,
provide attorneys reasonably acceptable to the affected Indemnitee(s) to defend against any actions
brought or filed against any Indemnitee(s) hereunder with respect to the subject of indemnity
contained herein, whether or not such actions are rightfully brought.

          (c) Beginning at the time any such product, process or service is being commercially
distributed or sold (including for the purpose of obtaining regulatory approvals) by Licensee or by
any sublicensee or agent of Licensee, Licensee shall, at its sole cost and expense, procure and
maintain commercial general liability insurance in amounts not less than $2,000,000 per incident
and $4,000,000 annual aggregate and naming the Indemnitees as additional insureds. During clinical
trials of any such product, process, or service, Licensee shall, at its sole cost and expense,
procure and maintain commercial general liability insurance in such equal or lesser amount as the
Foundation shall require, naming the Indemnitees as additional insureds. Such commercial general
liability insurance shall provide (i) product liability coverage and (ii) broad form contractual
liability coverage for Licensee’s indemnification under this Agreement. If Licensee elects to
self-insure all or part of the limits described above (including deductibles or retentions that are
in excess of $250,000 annual aggregate) such self-insurance program must be acceptable to the
Foundation and UTMDACC in their sole discretion. The minimum amounts of insurance coverage
required shall not be construed to create a limitation of Licensee’s liability with respect to its
indemnification under this Agreement.

          (d) Licensee shall provide the Foundation and UTMDACC with written evidence of such insurance
upon request of the Foundation or UTMDACC. Licensee shall provide the Foundation and UTMDACC with
written notice at least fifteen (15) days prior to the cancellation, non-renewal, or material
change in such insurance; if Licensee does not obtain

21

 

replacement insurance providing comparable coverage within such fifteen (15) day period, both
or one of the Foundation or UTMDACC shall have the right to terminate this Agreement effective at
the end of such fifteen (15) day period without notice or any additional waiting periods.

          (e) Licensee shall maintain such commercial general liability insurance beyond the expiration
or termination of this Agreement during (i) the period that any product, process, or service,
relating to, or developed pursuant to, this Agreement is being commercially distributed or sold by
Licensee or by a sublicensee or agent of Licensee and (ii) a reasonable period, but in no event
less than five (5) years, after the period referred to in clause (i), above.

     10.5 Limitation on Advertising and Publicity. Except as required by law, including
applicable rules and regulations of the U.S. Securities and Exchange Commission and stock exchange
listing requirements, Licensee shall not use the Foundation’s, UTMDACC’s, System’s, Board’s, or
USU’s name or insignia, or the name or insignia of the U.S. Government or any agency thereof, or
any adaptation of the foregoing, or the name of any of Foundation’s, UTMDACC’s, System’s, Board’s,
or USU’s inventors or employees, in any press release, public announcement, advertising,
promotional, or sales literature or its website or for the purpose of raising capital without the
prior written approval of the Foundation, UTMDACC, System, Board, or USU, as the case may be.
Advance express written consent of System, Board and UTMDACC may be secured through: The
University of Texas M. D. Anderson Cancer Center, Legal Services, Unit 0537, P.O. Box 301439,
Houston, TX 77230-1439, ATTENTION: Lori Stiffler, Email: [***]. Such consent shall be granted
(or denied) within a reasonable timeframe.

     10.6 Assignment. Neither this Agreement nor the rights granted hereunder shall be
transferred or assigned in whole or in part by Licensee to any person, whether voluntarily or
involuntarily, by operation of law, or otherwise, without the prior written consent of the
Foundation, which will not unreasonably be withheld or delayed. Notwithstanding the foregoing,
this Agreement and Licensee’s rights hereunder may be assigned or transferred to an entity that
acquires all or substantially all of the assets or business of Licensee or Licensee’s business unit
holding the License, whether through merger, sale of stock, sale of assets, reorganization, or
otherwise. This Agreement shall be binding upon and inure to the benefit of the Parties and their
respective successors, legal representatives, and permitted assignees.

     10.7 Compliance with Laws and Regulations. Licensee shall comply with all applicable
federal, state, and local laws and regulations, including U.S. Export Administration Regulations,
as well as end-user, end-use, and destination restrictions applied by the United States , and
international laws and regulations controlling exports,. Licensee agrees that it will be solely
responsible for any violation of applicable laws or regulations by Licensee or its Affiliates or
sublicensees, and that it will defend and hold the Owners harmless in the event of any legal action
of any nature occasioned by such violation.

     10.8 Regulatory Approvals; Patent Markings. Licensee agrees (i) to obtain all
regulatory approvals required for the manufacture and sale of Licensed Products and Licensed
Processes and (ii) to utilize appropriate patent marking on such Licensed Products. Licensee

22

 

also agrees to register or record this Agreement as is required by law or regulation in any
country where the License is in effect.

     10.9 Confidential Information and Intellectual Property. Except as specifically
required to comply with obligations set forth in this Agreement, no Party shall be obligated to
disclose or furnish to any other Party any Confidential Information of such first Party or any
confidential or proprietary information, technology, or intellectual property of any third party in
such first Party’s possession or control. If, however, all Parties have heretofore entered or
hereafter enter into a confidential information nondisclosure agreement or similar agreement (the
“NDA”), no Party may terminate the NDA prior to the termination or expiration of this Agreement.
If all Parties have not entered into an NDA, each Party agrees, for the greater of a period of five
(5) years after each disclosure or during the pendency of this Agreement, to maintain in confidence
all Confidential Information disclosed to it by another Party and to protect such Confidential
Information by using the same degree of care, but no less than a reasonable degree of care, as the
receiving Party uses to protect its own similar confidential information. For the avoidance of
doubt, neither Board nor UTMDACC shall be under any obligation to provide any information or
materials to Licensee under this Agreement.

     10.10 Headings. The article, section, and other headings contained in this Agreement
are for reference purposes only and are not intended to describe, interpret, define, or limit the
scope, extent, or intent of this Agreement.

     10.11 Waivers; Remedies Generally. The observance of any term of this Agreement may be
waived (whether generally or in a particular instance and either retroactively or prospectively) by
the Party entitled to enforce such term, but any such waiver will be effective only if in a writing
signed by the Party against which such waiver is to be asserted. Except as otherwise provided in
this Agreement, no failure or delay of any Party in exercising any power, right, or remedy under
this Agreement will operate as a waiver thereof, nor will any single or partial exercise of any
such right, power, or remedy, preclude any other or further exercise thereof or the exercise of any
other right, power, or remedy. A waiver by any Party shall be limited to the specific instance in
which it is given and, therefore, any waiver by any Party of any obligation of another Party under
or breach by another Party of this Agreement or of any power, right, or remedy of the waiving Party
shall not be a waiver of any other obligation or further or future performance of the same
obligation, of any other or succeeding breach, of any other or further exercise of such power,
right, or remedy or any other power, right, or remedy.

     10.12 Severability. To the extent that any provision of this Agreement shall be
judicially unenforceable in any one or more jurisdictions, such provision shall not be affected
with respect to any other jurisdiction, each provision with respect to each jurisdiction being
construed as several and independent. If any term or provision of this Agreement or the
application thereof to any person or circumstance is, to any extent, declared or found to be
illegal, unenforceable, or void, then all Parties will be relieved of all obligations arising under
such term or provision, but only to the extent that such term or provision is illegal,
unenforceable, or void, it being the intent and agreement of the Parties that this Agreement will
be deemed amended by modifying such term or provision to the extent necessary to make it legal and
enforceable while preserving its intent or, if that is not possible, by substituting

23

 

therefor another term or provision that is legal and enforceable and achieves the same
objective. If the remainder of this Agreement will not be affected by such declaration or finding
and is capable of substantial performance, then each term and provision not so affected will be
enforced to the extent permitted by law. If necessary to effect the intent of the Parties, the
Parties will negotiate in good faith to amend this Agreement to replace the unenforceable language
with enforceable language that as closely as possible reflects such intent and to amend any other
term or provision thereby rendered incapable of substantial performance or otherwise affected
thereby to the extent necessary to permit the practical realization, insofar as legally possible,
of the intent of the Parties.

     10.13 Relationship of the Parties; Disclaimer of Agency.

          (a) Independent Contractors. In entering into and carrying out this Agreement, the
Parties will be acting solely as independent contractors. Nothing in this Agreement creates, has
created, or will create any partnership, joint venture, or other business association between the
Parties, nor any duties or responsibilities of partners, venturers, or members of a business
association.

          (b) No Agency. Except for provisions in this Agreement expressly authorizing one
Party to act for the other, this Agreement will not constitute any Party as a legal representative
or agent of another Party, nor will any Party have the right or authority to assume, create, or
incur any liability or any obligation of any kind, expressed or implied, against or in the name or
on behalf of another Party unless otherwise expressly permitted by such Party.

     10.14 No Third-Party Beneficiaries. The representations, warranties, covenants, and
undertakings contained in this Agreement are for the sole benefit of the Parties, their
sublicensees, and the Parties’ permitted successors and assigns and shall not be construed as
creating any third party beneficiaries of this Agreement or as conferring any rights whatsoever on
any third party.

     10.15 Notices. Unless otherwise expressly agreed by the Party receiving notice, any
notice, demand, or other communication required or permitted to be given by any Party under any
provision of this Agreement must be in writing, in the English language, and mailed (certified or
registered mail, postage prepaid, return receipt requested) or sent by hand or overnight courier,
charges prepaid and addressed to the intended recipient at such Party’s address set forth below, or
to such other address or number as such Party may from time to time specify by notice to the other
Party(ies) as provided in this Section. All notices and other communications given in accordance
with the provisions of this Agreement will be deemed to have been given and received when actually
delivered by hand, by mail, or by courier.

24

 

If to Licensee:

RXi Pharmaceuticals Corporation

60 Prescott Street

Worcester, Massachusetts 01605

Attention: President and Chief Executive Officer

If to the Foundation:

The Henry M. Jackson Foundation for

the Advancement of Military Medicine, Inc.

6720-A Rockledge Drive, Suite 100

Bethesda, Maryland 20817

Attention: General Counsel

     If to UTMDACC:

The University of Texas M. D. Anderson Cancer Center

Office of Technology Commercialization

7515 S. Main, Suite 490, Unit 0510

Houston, Texas 77030

ATTENTION: Christopher C. Capelli

with copy to Board:

BOARD OF REGENTS

The University of Texas System

201 West Seventh Street

Austin, Texas 78701

ATTENTION: Office of General Counsel.

     10.16 Entire Agreement; Modifications. This Agreement constitutes the complete
agreement between the Parties concerning the subject matter hereof and replaces any prior oral or
written communications between the Parties. There are no conditions, understandings, agreements,
representations, or warranties, express or implied, that are not specified herein, and no Party
shall be obligated by any condition or representation other than those expressly stated herein or
as may be subsequently agreed by the Parties in writing. Any purported modification or amendment
of the express terms or provisions of this Agreement shall be effective only if contained in a
written instrument signed by each Party. Notwithstanding the foregoing, any Amendment to this
Agreement concerning Foundation Follow-on Intellectual Property shall require only the signatures
of Foundation and Licensee. Notwithstanding the foregoing, nothing in this Agreement replaces,
modifies, or supersedes the terms and conditions of the Amended

25

 

and Restated Inter-Institutional Sharing Agreement between Board, UTMDACC and Foundation
having an effective date of July 8, 2009.

     10.17 Force Majeure. No Party shall be liable to any other Party for any losses or
damages to the extent and for the period of time that they are attributable to a default or breach
of this Agreement that is the result of war (whether declared or undeclared), acts of God,
revolution, acts of terrorism, fire, earthquake, flood, pestilence, riot, enactment of change of
law following the Effective Date, accident, labor trouble, or shortage of or inability to obtain
material equipment or transport or any other cause beyond the reasonable control of such Party;
provided, however, that if such a cause occurs, then the Party affected will promptly notify the
other Party(ies) of the nature and likely result and duration (if known) of such cause and use
commercially reasonable efforts to mitigate any adverse effects under this Agreement. If the event
lasts for a period longer than three (3) months, the Parties shall meet and discuss appropriate
modifications to this Agreement or other remedial measures.

     10.18 Covenant. Licensee, by execution hereof, acknowledges, covenants and agrees
that Licensee has not been induced in any way by Foundation, Board, System, UTMDACC or employees
thereof to enter into this Agreement, and further warrants and represents that (a) Licensee has
conducted sufficient due diligence with respect to all items and issues pertaining to this
Agreement; and (b) Licensee has adequate knowledge and expertise, or has used knowledgeable and
expert consultants, to adequately conduct such due diligence, and agrees to accept all risks
inherent herein.

     10.19 Late Payment Rates. If and only to the extent that this Agreement would require
any interest rate to be applied to any late payments owed directly to Board or UTMDACC,
notwithstanding anything to the contrary set forth in this Agreement, such rate payable to Board or
UTMDACC shall not exceed the maximum rate allowed by applicable law.

     10.20 Sovereign Immunity. The Parties acknowledge that Board, System and UTMDACC are
agencies of the State of Texas and under the Constitution and laws of the State of Texas possess
certain rights and privileges and only have such authority as is granted to them under the
Constitution and laws of the State of Texas. Nothing in this Agreement is intended to be, nor will
it be construed to be, a waiver of the sovereign immunity of the State of Texas, System, Board, or
UTMDACC or a prospective waiver or restriction of any of the rights, remedies, claims, and
privileges of the State of Texas, System, Board, or UTMDACC. Nothing in this Agreement shall be
construed as an obligation or agreement by System, Board or UTMDACC to join as a party to
litigation. Moreover, notwithstanding the generality or specificity of any provision hereof, the
provisions of this Agreement, with respect to Board, System and UTMDACC, are enforceable only to
the extent authorized by the Constitution and laws of the State of Texas. Nothing in this
Agreement shall be construed to require Board, System or UTMDACC to perform any act or to refrain
from any act that would violate any state or federal law. This Agreement is subject to, and the
Parties agree to comply with, all applicable local, state, and federal laws, statutes, rules and
regulations. Any provision of any applicable law, statute, rule or regulation that invalidates any
provision of this Agreement, that is inconsistent with any provision of this Agreement, or that
would cause one or both of the Parties hereto to be in violation of law will be deemed to have
superseded the terms of this

26

 

Agreement. The Parties, however, will use commercially reasonable efforts to accommodate the
terms and intent of this Agreement to the greatest extent possible consistent with the requirements
of the law and negotiate in good faith toward amendment of this Agreement in such respect.

SIGNATURE PAGE FOLLOWS

27

 

THE FOUNDATION, BOARD, UTMDACC, AND LICENSEE HAVE READ THIS AGREEMENT INCLUDING ALL APPENDICES
HERETO AND AGREE TO BE BOUND BY ALL THE TERMS AND CONDITIONS HEREOF AND THEREOF.

     IN WITNESS WHEREOF, the Parties have entered into this License Agreement as of the Effective
Date.

	 	 	 

	THE HENRY M. JACKSON

	 	 
	FOUNDATION FOR THE
	 	 
	ADVANCEMENT OF MILITARY
	 	 
	MEDICINE, INC.
	 	 
	 
	 	 
	/s/ John W. Lowe
	 	 
	 

John W. Lowe

	 	 
	President & CEO
	 	 
	 
	 	 	 	 
	8/24/11
	 	 
	 

	Date
	 	 
	 
	 	 
	RXI PHARMACEUTICALS
	 	 
	CORPORATION
	 	 
	 
	 	 
	/s/ Mark J. Ahn, Ph.D.
	 	 
	 

Mark J. Ahn, Ph.D.

	 	 
	President and CEO
	 	 
	 
	 	 
	8/23/11
	 	 
	 

	Date
	 	 

	 	 	 	 	 

	BOARD OF REGENTS OF THE	 	 
	UNIVERSITY OF TEXAS SYSTEM	 	 
	 
	 	 	 	 
	By
	 	/s/ John Mendelsohn, M.D.	 	 
	 

	 	 

John Mendelsohn, M.D.
	 	 
	 

	 	President	 	 
	 

	 	The University of Texas	 	 
	 

	 	M. D. Anderson Cancer Center	 	 
	 
	 	 	 	 
	9/16/11
	 	 	 	 
	 

	Date
	 	 	 	 

	 	 	 	 	 

	THE UNIVERSITY OF TEXAS	 	 
	M. D. ANDERSON CANCER CENTER	 	 
	 
	 	 	 	 
	By

	 	/s/ Leon Leach	 	 
	 

	 	 

Leon Leach
	 	 
	 

	 	Executive Vice President	 	 
	 

	 	The University of Texas	 	 
	 

	 	M. D. Anderson Cancer Center	 	 
	 
	 	 	 	 
	9/13/11
	 	 	 	 
	 

	Date
	 	 	 	 

	 	 	 	 	 

	Approved as to Content:	 	 
	 
	 	 	 	 
	By

	 	/s/ Christopher C. Capelli	 	 
	 

	 	 

Christopher C. Capelli
	 	 
	 

	 	Vice President, Technology Transfer	 	 
	 

	 	M. D. Anderson Cancer Center	 	 
	 
	 	 	 	 
	8/30/11
	 	 	 	 
	 

	Date
	 	 	 	 

28

 

APPENDIX A

     The following patent applications are included in the Patent Rights:

	 	 	 

	Title:

	 	HJF 068-01 “Induction of Tumor Immunity by Variants of Folate
Binding Protein.”
	 
	 	 
	Inventors:

	 	Constantine G. Ioannides, Ph.D. and George E. Peoples, Jr., M.D.
	 
	 	 
	 

	 	as described in U.S. Provisional Application No. 60/274,676
filed on 03/09/2001; and
	 
	 	 
	 

	 	as described in U.S. Patent Application No. 10/094,097 and
International Patent Application No. PCT/US2002/007167 filed on
03/08/2002, claiming priority to U.S. Provisional Application
No. 60/274,676, and all corresponding National Stage
Applications including but not limited to Canadian Patent
Application No. 2,440,610 filed on 09/04/2003, Japanese Patent
Application No. 2002-571822 filed on 09/08/2003, and European
Patent Application No. 02750589.0 filed on 10/07/2003; and
	 
	 	 
	 

	 	as described in U.S. Patent Application No. 12/422,600 filed on
04/13/2009, claiming priority to U.S. Patent Application No.
10/094,097; and
	 
	 	 
	 

	 	as described in Japanese Patent Application No. 2008-289217
filed on 05/28/2009, claiming priority to Japanese Patent
Application No. 2002-571822.

29

 

APPENDIX B

     Follow-on Intellectual Property

30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]